Clearmind Medicine (CMND) 20-F 22 Jan 25 2024 FY Annual report (foreign) Financial data

Cover

Cover	12 Months Ended
	Oct. 31, 2024 shares
Document Information [Line Items]
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Financial Statement Error Correction [Flag]	false
Document Shell Company Report	false
Entity Interactive Data Current	Yes
Document Accounting Standard	International Financial Reporting Standards
ICFR Auditor Attestation Flag	true
Amendment Flag	false
Document Period End Date	Oct. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Entity Information [Line Items]
Entity Registrant Name	Clearmind Medicine Inc.
Entity Central Index Key	0001892500
Entity File Number	001-41557
Entity Incorporation, State or Country Code	A1
Current Fiscal Year End Date	--10-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	101 – 1220 West 6th Avenue
Entity Address, City or Town	Vancouver
Entity Address, Country	CA
Entity Address, Postal Zip Code	V6H1A5
Entity Listings [Line Items]
Title of 12(b) Security	Common shares, no par value per share
Trading Symbol	CMND
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding	4,265,186
Business Contact [Member]
Entity Contact Personnel [Line Items]
Contact Personnel Name	Dr. Adi Zuloff-Shani
Contact Personnel Email Address	invest@clearmindmedicine.com
Entity Address, Address Line One	101 – 1220 West 6th Avenue
Entity Address, City or Town	Vancouver
Entity Address, Country	CA
Entity Address, Postal Zip Code	V6H1A5
Entity Phone Fax Numbers [Line Items]
City Area Code	973
Local Phone Number	536.1016

Audit Information

Audit Information	12 Months Ended
	Oct. 31, 2024
Auditor [Table]
Auditor Name	Brightman Almagor Zohar & Co.
Auditor Firm ID	1197
Auditor Location	Tel Aviv, Israel

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($)	Oct. 31, 2024	Oct. 31, 2023
Current assets
Cash and cash equivalents	$ 6,573,813	$ 5,427,739
Other receivables	49,038	104,320
Short-term investments (Note 5)	289,388	86,112
Prepaid expenses	44,161	40,403
Related parties (Note 6b)	131,839	136,002
Total current assets	7,088,239	5,794,576
Non-current assets
Property and equipment		1,727
Intangible assets (Note 3)	108,326	119,310
Restricted cash	7,186	37,675
Right-of-use asset (Note 4)	51,663
Total non-current assets	167,175	158,712
Total assets	7,255,414	5,953,288
Current liabilities
Accounts payable and accrued liabilities	526,056	617,004
Due to related parties (Note 6)	48,962	42,433
Derivative warrant liabilities (Note 7)	3,519,702	4,310,379
Short-term portion of lease liabilities (Note 4)	36,726
Total current liabilities	4,131,446	4,969,816
Non- current liabilities
Long-term lease liabilities (Note 4)	16,416
Total non- current liabilities	16,416
Total liabilities	4,147,862	4,969,816
Shareholders’ equity
Share capital and share premium (Note 8)	24,168,256	17,131,223
Warrants (Note 9)	459,341	459,341
Share-based payment reserve (Notes 10,11)	2,523,946	2,182,221
Accumulated other comprehensive loss	(21,250)	(21,250)
Accumulated deficit	(24,022,741)	(18,768,063)
Total shareholders’ equity	3,107,552	983,472
Total liabilities and shareholders’ equity	$ 7,255,414	$ 5,953,288

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)		12 Months Ended
		Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2022
Operating expenses
General and administrative (Note 17)		$ 4,362,117	$ 4,759,205	$ 3,170,440
Research and development, net (Note 18)		1,382,808	1,544,229	3,080,991
Total operating expenses		5,744,925	6,303,434	6,251,431
Finance income (expenses)
Changes in fair value of derivative warrant liabilities (Notes 7, 8e (iii))		707,802	(2,189,986)	(290,569)
Changes in fair value of short-term investments Note 5)		(68,624)	(107,638)	(308,188)
Foreign exchange loss		(6,028)	(78,136)	(404)
Other finance expenses		(36,161)	(10,894)	(14,417)
Interest income on deposit		271,224	70,068
Total finance income (expenses)		868,213	(2,316,586)	(613,578)
Other income
Dividend received			16,555
Total other income			16,555
Loss Before taxes		(4,876,712)	(8,603,465)	(6,865,009)
Tax expenses		(377,966)	(17,372)	(29,859)
Net Loss		(5,254,678)	(8,620,837)	(6,894,868)
Items that may be reclassified subsequently to profit or loss:
Foreign exchange differences on translation of foreign operations				(21,250)
Total comprehensive loss		$ (5,254,678)	$ (8,620,837)	$ (6,916,118)
Loss per share , basic (in Dollars per share)		$ (1.69)	$ (42.58)	$ (159.11)
Loss per share , diluted (in Dollars per share)		$ (1.69)	$ (42.58)	$ (159.11)
Weighted average number of shares for the purposes of basic and diluted loss per share (in Shares)	[1]	3,100,131	202,481	43,335
Weighted average number of shares for the purposes of diluted loss per share (in Shares)	[1]	3,100,131	202,481	43,335
[1] On September 30, 2022 and on November 28, 2023, the Company effected 1-for-30 reverse splits of its issued and outstanding common shares, pursuant to which holders of the Company’s common shares received 0.0333 of a common share for every one common share. All share amounts have been retroactively restated for all periods presented.

Statements of Changes in Shareh

Statements of Changes in Shareholders’ Equity (Deficit) - USD ($)		Share capital and share premium	Warrants	Share-based payment reserve	Accumulated other comprehensive income	Accumulated deficit	Total
Balance Beginning at Oct. 31, 2021		$ 5,792,009	$ 250,567	$ 727,860		$ (3,252,358)	$ 3,518,078
Balance Beginning (in Shares) at Oct. 31, 2021	[1]	41,695
Net loss for the year						(6,894,868)	(6,894,868)
Foreign currency translation gain					(21,250)		(21,250)
Total comprehensive loss for the year					(21,250)	(6,894,868)	(6,916,118)
Common shares for services		$ 38,684		107,222			145,906
Common shares for services (in Shares)	[1]	89
Units issued for cash		$ 559,118	139,779				698,897
Units issued for cash (in Shares)	[1]	1,325
Issuance costs		$ (55,912)	(13,978)				(69,890)
Units issued for short-term investment		$ 372,745	82,742				455,487
Units issued for short-term investment (in Shares)	[1]	883
Share-based compensation				1,061,642			1,061,642
Share-based compensation (in Shares)
Balance Beginning at Oct. 31, 2022		$ 6,706,644	459,110	1,896,724	(21,250)	(10,147,226)	(1,105,998)
Balance Beginning (in Shares) at Oct. 31, 2022	[1]	43,992
Net loss for the year						(8,620,837)	(8,620,837)
Issuance of common shares		$ 6,026,327		337,579			6,363,906
Issuance of common shares (in Shares)	[1]	38,462
Common shares and warrants issued to XYLO TECHNOLOGIES LTD. (formerly Medigus Ltd.)		$ 296,845	231				297,076
Common shares and warrants issued to XYLO TECHNOLOGIES LTD. (formerly Medigus Ltd.) (in Shares)	[1]	1,494
Issuance of common shares, pre-funded warrants and warrants (Note 8c(iii))		$ 1,455,832					1,455,832
Issuance of common shares, pre-funded warrants and warrants (Note 8c(iii)) (in Shares)	[1]	150,191
Issuance of common shares upon vesting of restricted stock units (Note 8c(vi,viii,xi,xiii))		$ 263,408		(263,408)
Issuance of common shares upon vesting of restricted stock units (Note 8c(vi,viii,xi,xiii)) (in Shares)	[1]	1,391
Issuance of common shares, pre-funded warrants and warrants		$ 1,069,478					1,069,478
Issuance of common shares, pre-funded warrants and warrants (in Shares)	[1]	250,000
Exercise of warrants (Notes 8c(ii, v, ix,xii))		$ 1,164,117					1,164,117
Exercise of warrants (Notes 8c(ii, v, ix,xii)) (in Shares)	[1]	119,433
Foreign currency translation gain
Total comprehensive loss for the year							(8,620,837)
Common shares for services		$ 148,572		(101,888)			46,684
Common shares for services (in Shares)	[1]	2,374
Share-based compensation				313,214			313,214
Share-based compensation (in Shares)
Balance Beginning at Oct. 31, 2023		$ 17,131,223	459,341	2,182,221	(21,250)	(18,768,063)	983,472
Balance Beginning (in Shares) at Oct. 31, 2023	[1]	607,337
Net loss for the year						(5,254,678)	(5,254,678)
Issuance of common shares, pre-funded warrants and warrants (Note 8c(iii))		$ 1,459,815					1,459,815
Issuance of common shares, pre-funded warrants and warrants (Note 8c(iii)) (in Shares)	[1]	1,500,000
Issuance of common shares upon vesting of restricted stock units (Note 8c(vi,viii,xi,xiii))		$ 541,835		(541,835)
Issuance of common shares upon vesting of restricted stock units (Note 8c(vi,viii,xi,xiii)) (in Shares)		329,338
Exercise of warrants (Notes 8c(ii, v, ix,xii))		$ 4,667,400					4,667,400
Exercise of warrants (Notes 8c(ii, v, ix,xii)) (in Shares)		1,569,866
Foreign currency translation gain
Total comprehensive loss for the year							(5,254,678)
Share-based compensation		$ 367,983		883,560			1,251,543
Share-based compensation (in Shares)		258,645
Balance Beginning at Oct. 31, 2024		$ 24,168,256	$ 459,341	$ 2,523,946	$ (21,250)	$ (24,022,741)	$ 3,107,552
Balance Beginning (in Shares) at Oct. 31, 2024	[1]	4,265,186
[1] On September 30, 2022 and on November 28, 2023, the Company effected 1-for-30 reverse splits of its issued and outstanding common shares, pursuant to which holders of the Company’s common shares received 0.0333 of a common share for every one common share. All share amounts have been retroactively restated for all periods presented.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2022
Operating activities
Net loss	$ (5,254,678)	$ (8,620,837)	$ (6,894,868)
Adjustments for:
Amortization of intangible assets	10,984	10,954	14,830
Amortization of right-of-use asset	39,023	35,381	60,665
Interest on lease liability	5,386	2,907	14,433
Exchange rate differences	6,051	78,171
Issuance costs allocated to derivate warrant liability	115,046	468,408
Depreciation of property and equipment	1,065	11,175	7,572
Changes in fair value of derivative warrant liabilities	(707,802)	2,189,986	290,569
Share-based compensation	883,872	366,405	1,207,549
Changes in fair value of short-term investments	68,624	107,638	308,187
Tax expenses	103,879	17,372	29,859
Changes in working capital:
Decrease (increase) in other receivables	64,949	(154,621)	19,938
Decrease (increase) in prepaid expenses	(3,690)	(26,134)	103,026
Increase (decrease) in accounts payable and accrued liabilities	(198,590)	(620,421)	913,303
Increase (decrease) in amounts due to / from related parties	7,222	(167,856)	200,443
Net cash used in operating activities	(4,858,659)	(6,301,472)	(3,724,494)
Investing activities
Proceeds from sale of short-term investment (Note 5)	78,500
Purchase of securities (Note 5)	(350,400)
Changes in restricted cash	33,803	(26,228)
Acquisition of property and equipment			(5,563)
Net cash used in investing activities	(238,097)	(26,228)	(5,563)
Financing activities
Proceeds from issuance of common shares and warrants, net of issuance costs (Notes 7, 8c)	2,192,444	11,115,241	582,558
Proceeds received from exercise of warrants (Note 7)	4,104,521	590,077
Repayment of lease liabilities	(42,587)	(40,922)	(70,870)
Net cash provided by financing activities	6,254,378	11,664,396	511,688
Effect of foreign exchange rate changes on cash and cash equivalents	(11,548)	(37,734)	(22,652)
Net increase (decrease) in cash and cash equivalents	1,146,074	5,298,962	(3,241,021)
Cash and cash equivalents at beginning of year	5,427,739	128,777	3,369,798
Cash and cash equivalents at end of year	6,573,813	5,427,739	128,777
Supplementary disclosure of cash flow information:
Cash received as interest	271,784	71,733	8
Dividend received		16,555
Cash paid for taxes	306,592	12,678
Interest on lease liability	5,386	2,907	14,433
Non-cash financing and investing activities
Common shares issued to Xylo Technologies Ltd. (formerly known as Medigus Ltd.) (Note 8d(i))		296,569
Right of use assets obtained in exchange for lease liabilities	181,779		92,731
Early termination of office lease (Note 4)	(88,562)
Shares obtained from Xylo Technologies Ltd. (formerly known as Medigus Ltd.) in issuance of shares and warrants			455,488
Deferred offering costs included in non-current assets			$ 198,173

Nature of Operations and Going

Nature of Operations and Going Concern	12 Months Ended
	Oct. 31, 2024
Nature of Operations and Going Concern [Abstract]
Nature of Operations and Going Concern	1. Nature of Operations and Going Concern a. Clearmind Medicine Inc. (the “Company”) was incorporated in the province of British Columbia on July 18, 2017. The Company is a clinical pharmaceutical company currently engaged in phase I/IIa clinical trials of novel psychedelic medicines that have been developed to solve widespread, yet under-served, health problems. The Company’s head office is located at Suite 101 -1220 West 6 th On November 14, 2022, the Company completed a listing on the Nasdaq Capital Market (“Nasdaq”). The Company trades under the symbol “CMND” on the Nasdaq and on the Frankfurt Stock Exchange, (FSE), under the symbol “CWY”. The Company was listed on the Canadian Securities Exchange (“CSE”) in Toronto until March 14, 2024. Following approval for a voluntary delisting, the Company no longer trades on the CSE but remains a reporting issuer in Canada. On April 6, 2023, the Company completed an underwritten public offering for aggregate gross proceeds of $3.5 million and net proceeds of $2.9 million. See note 8d (iii). On September 18, 2023, the Company completed an underwritten public offering for aggregate gross proceeds of $2.25 million and net proceeds of $1.8 million. See note 8d (viii). On January 16, 2024, the Company completed a registered direct and private placement for aggregate gross proceeds of $2.40 million. See note 8b (iii). b. Going concern These consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. For the year ended October 31, 2024, the Company did not generate any revenues and had negative cash flow from operations of $4,858,659. As of October 31, 2024, the Company had an accumulated deficit of $24,022,741. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing through debt or equity. Management is of the opinion that sufficient working capital will be obtained from external financing to meet the Company’s liabilities and commitments as they become due, although there is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company. These factors raise substantial doubt on the Company’s ability to continue as a going concern. These consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern. c. Reverse share split On September 30, 2022, the Company’s Board of Directors (the “Board”) approved a 1-for-30 reverse split of its issued and outstanding common shares, effective as of September 30, 2022, pursuant to which holders of the Company’s common shares received 0.0333 of a common share for every one common share. On November 28, 2023, the Board approved a 1-for-30 reverse split of its issued and outstanding common shares, effective as of November 28, 2023, pursuant to which holders of the Company’s common shares received 0.0333 of a common share for every one common share then held. All issued and outstanding common shares or instruments convertible into common shares contained in these financial statements have been retroactively adjusted to reflect the reverse share splits for all periods presented, unless explicitly stated otherwise. d. Functional Currency and Presentation Currency As a result of the Company’s listing on the Nasdaq, which was completed in November 2022, the primary economic environment and generation and use of cash flows of the Company became mainly denominated in U.S dollars. Consequently, effective on November 1, 2022, the Company changed both its functional currency and the presentation currency of its consolidated financial statements from the Canadian dollar to the U.S dollar. The Company is in its research and development stages and has not generated revenues since inception. In consideration of the indicators in IAS 21, the Company determined that the new and future financing activities of the Company and the currency in which cash and cash equivalents are retained were relevant factors indicating that the Canadian dollar will not be the currency to reflect the principal economic environment in which the Company will generate and expend its cash. Under IAS 21, a change in an entity’s functional currency is applied prospectively from the date of the change. The Company applied the practical expedient to apply the transaction procedures applicable to the new functional currency prospectively beginning on November 1, 2022. The change in the functional currency was accounted for prospectively from the date of the change by translating all items of the financial statement into the new functional currency using the exchange rate of $0.7327 CAD/USD at the date of the change. The change in the presentation currency of the consolidated financial statement was accounted for as a change in accounting policy and applied retrospectively, as if the new presentation currency had always been the presentation currency of the consolidation financial statements. Consequently, comparative figures for the years prior to the effective date of November 1, 2022 have been restated to the new presentation currency using the exchange rate in effect on effective date of the change. Following the change in the Company’s functional currency, the Company elected, as an accounting policy, not to reclassify instruments which, had the change in functional currency occurred before initial recognition of the instrument, would have changed its classification. e. In October 2023, Israel was attacked by a terrorist organization and entered a state of war. In addition, there have been continued hostilities along Israel’s northern border with Lebanon (with the Hezbollah terror organization) and on other fronts from various extremist groups in the region, such as the Houthis in Yemen and various rebel militia groups in Syria and Iraq. Israel has carried out a number of targeted strikes on sites belonging to these terror organizations. In October 2024, Israel began limited ground operations against Hezbollah in Lebanon, and in November 2024, a ceasefire was brokered between Israel and Hezbollah. In addition, Iran recently launched direct attacks on Israel involving hundreds of drones and missiles and has threatened to continue to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve. The war is on-going as of the issuance date of these financial statements. The Company’s clinical trials, the laboratory that supports such clinical trials and the Contract Research Organization (CRO) are based in Israel. The extent to which the War may impact the Company’s financial condition, results of operations, or liquidity is uncertain, and as of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or an adjustment to the carrying value of the Company’s assets or liabilities as of October 31, 2024.

Material Accounting Policies

Material Accounting Policies	12 Months Ended
	Oct. 31, 2024
Material Accounting Policies [Abstract]
Material Accounting Policies	2. Material Accounting Policies a. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) on a going concern basis. These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Clearmindmed Ltd. and Clearmind Labs Corp. (inactive). All inter-company balances and transactions have been eliminated on consolidation. These consolidated financial statements have been prepared on a historical cost basis, except for financial assets and liabilities (including derivatives) which are presented at fair value through profit or loss (“FVTPL”) and are presented in U.S. dollars, which is the Company’s functional currency as of November 1, 2022. b. Significant Accounting Estimates and Judgments The preparation of consolidated financial statements in accordance with IFRS requires management to make judgments, estimates, and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Significant Estimates Share-based Compensation Fair values are determined using the Black-Scholes option pricing model. Estimating fair value requires determining the most appropriate valuation model for a grant of equity instruments, which is dependent on the terms and conditions of the grant. Option-pricing models require the use of highly subjective estimates and assumptions including the expected stock price volatility. Changes in the underlying assumptions can materially affect the fair value estimates and, therefore, existing models do not necessarily provide reliable measurement of the fair value of the Company’s stock options. Derivative Warrant Liabilities and Assets The Company analyses warrants issued to determine whether they meet the classification as liabilities or equity. Derivative warrant liabilities and assets are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations. The Company uses a fair valuation specialist to estimate the value of these instruments using the Black and Scholes and binomial pricing model. The key assumptions used in the models are the expected future volatility in the price of the Company’s shares, the expected life of the warrants, the risk-free interest rate and the probability of any future adjustment event. Significant Judgments The critical judgments that the Company’s management has made in the process of applying the Company’s accounting policies that have the most significant effect on the amounts recognized in the Company’s consolidated financial statements are as follows: Going Concern The application of the going concern assumption requires management to take into account all available information about the future, which is at least but not limited to, 12 months from the year end of the reporting period. The Company is aware that material uncertainties related to events or conditions raise substantial doubt upon the Company’s ability to continue as a going concern. c. Cash and Cash Equivalents The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance, which are readily convertible to known amounts of cash, and which are subject to insignificant risk of changes in value to be cash equivalents. d. Provisions Provisions are recognized where a legal or constructive obligation has been incurred as a result of past events; it is probable that an outflow of resources embodying economic benefit will be required to settle the obligation; and a reliable estimate of the amount of the obligation can be made. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation. e. Intangible Assets Intangible assets consist of patents and patent applications acquired to be used in drug research programs. Intangible assets are carried at cost less accumulated amortization and impairment losses and are capitalized when the costs can be measured reliably, and it is probable that future economic reliably benefits that are attributable to the asset will flow to the Company. The Company amortizes patents over the term of the patent. f. Financial Instruments Financial assets and financial liabilities are recognized when the Company becomes a party to the contractual provisions of the respective instrument. Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities (other than financial assets and financial liabilities at FVTPL) are included in the initial carrying value of the related instrument and are amortized using the effective interest method. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognized immediately in the consolidated statement of operations and comprehensive loss. Financial assets The classification of financial assets depends on the nature and purpose of the financial assets and is determined at the time of initial recognition. Financial assets at FVTPL Financial assets are classified as FVTPL when the financial asset is either held for trading or it is designated as FVTPL. A financial asset is classified as held for trading if: ● it has been acquired principally for the purpose of selling it in the near term; or ● on initial recognition it is part of a portfolio of identified financial instruments that the Company manages together and has a recent actual pattern of short-term profit-taking. Financial assets at amortized cost Financial assets at amortized cost are non-derivative financial assets which are held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. A financial asset (unless it is a trade receivable without a significant financing component that is initially measured at the transaction price) is initially measured at fair value plus, for an item not at FVTPL, transaction costs that are directly attributable to its acquisition. Subsequent to initial recognition, financial assets are measured at amortized cost using the effective interest method, less any impairment. Financial liabilities and equity instruments Classification as debt or equity Debt and equity instruments issued by the Company are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. Equity instruments An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognized as the proceeds received, net of direct issue costs. Other financial liabilities All financial liabilities are measured subsequently at amortized cost using the effective interest method or at FVTPL. Financial liabilities at FVTPL Financial liabilities are classified as at FVTPL when the financial liability is (i) contingent consideration of an acquirer in a business combination, (ii) held for trading or (iii) it is designated as at FVTPL. A financial liability is classified as held for trading if either: ● It has been acquired principally for the purpose of repurchasing it in the near term ● On initial recognition it is part of a portfolio of identified financial instruments that the group manages together and has a recent actual pattern of short-term profit-taking ● It is a derivative, except for a derivative that is a financial guarantee contract or a designated and effective hedging instrument Financial liabilities at FVTPL are measured at fair value, with any gains or losses arising on changes in fair value recognized in profit or loss. Financial liabilities measured subsequently at amortized cost Financial liabilities that are not (i) contingent consideration of an acquirer in a business combination, (ii) held-for-trading, or (iii) designated as at FVTPL, are measured subsequently at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or (where appropriate) a shorter period, to the amortized cost of a financial liability. g. Income Taxes Current income tax The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in profit or loss because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The Company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred income tax Deferred income tax is provided using the statement of financial position method on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred income tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that sufficient taxable income will be available to allow all or part of the deferred income tax asset to be utilized. Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred income tax assets and deferred income tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred income taxes relate to the same taxable entity and the same taxation authority. h. Foreign Currency Translation The Company’s reporting currency is the United States dollar. The functional currency for the Company and its subsidiary is the currency of the primary economic environment in which the entity operates. As of November 1, 2023, the functional currency of the Company and its Canadian and Israeli subsidiaries is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated using the exchange rate in effect on the transaction date or at the annual average rate. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange in effect at the consolidated statement of financial position date. Non-monetary items are translated using the historical rate on the date of the transaction. Foreign exchange gains and losses are included in the consolidated statement of operations and comprehensive loss. i. Share-based Payments The grant date fair value of share-based payment awards granted to employees is recognized as stock-based compensation expense, with a corresponding increase in equity, over the period that the employees unconditionally become entitled to the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant date fair value of the share-based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcomes. Where equity instruments are granted to parties other than employees, they are recorded by reference to the fair value of the services received. If the fair value of the services received cannot be reliably estimated, the Company measures the services received by reference to the fair value of the equity instruments granted, measured at the date the counterparty renders service. The fair value of services received from consultants cannot be reliably measured; therefore, the fair value of the underlying equity instruments was utilized for all periods presented. All equity-settled share-based payments are reflected in share-based payment reserve, unless exercised. Upon exercise, shares are issued and the amount reflected in share-based payment reserve is credited to share capital, adjusted for any consideration paid. j. Restricted Share Units The Company recognizes compensation expense for restricted share units (“RSU’s”) awarded based on the grant-date fair value of the common shares. The grant-date fair value, which is determined by multiplying the Company’s share price by the number of RSU’s granted, is amortized over the vesting period and is included in compensation expense with a corresponding increase in the share-based payment reserve. If RSU’s are for services that have been provided and are non-cancellable, the Company recognizes the full cost of the RSU’s on the date of grant. The amount recognized is adjusted to reflect the number of RSU’s expected to eventually vest. k. Leases The Company’s Israeli subsidiary leased an office through to March 31, 2026. At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company reassesses whether a contract is, or contains, a lease only if the terms and conditions of the contract are changed. At the commencement date, the Company measures the lease liability at the present value of the lease payments that are not paid at that date, including, inter alia, the exercise price of a purchase option if the Company is reasonably certain to exercise that option. Simultaneously, the Company recognizes a right-of-use (“ROU”) asset in the amount of the lease liability. The discount rate applied by the Company is the rate of interest that the Company would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the ROU asset in a similar economic environment. The weighted average of lessee’s incremental annual borrowing rate applied to the lease liabilities as of October 31, 2024 was estimated at 10%. The lease term is the non-cancellable period for which the Company has the right to use an underlying asset, together with both, the periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option and periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option. After the commencement date, the Company measures the ROU asset applying the cost model, less any accumulated depreciation and any accumulated impairment losses and adjusted for any remeasurement of the lease liability. Assets are depreciated by the straight-line method over the estimated useful lives of the ROU asset or the lease period, whichever is shorter. Interest on the lease liability is recognized in profit or loss in each period during the lease term in an amount that produces a constant periodic rate of interest on the remaining balance of the lease liability. The Company applied the following practical expedients: ● Non-lease components: practical expedient by class of underlying asset not to separate non-lease components (services) from lease components and, instead, account for each lease component and any associated non lease components as a single lease component. ● The practical expedient for short-term leases is applied. l. Research and Development Research costs are charged to operations as incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably, the product is technically and commercially feasible, future economic benefits are probable, and the Company intends to or has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized includes the cost of materials, direct labor and overhead costs that are directly attributable to preparing the asset for its intended use and borrowing costs on qualifying assets. Other development expenditures are recognized in the consolidated statement of operations and comprehensive loss as incurred. The Company has not capitalized any development costs for the years ended October 31, 2024, 2023 and 2022. m. Loss Per Share Basic loss per share is computed using the weighted average number of common shares outstanding during the period. The treasury stock method is used for the calculation of diluted loss per share, whereby all “in the money” stock options and share purchase warrants are assumed to have been exercised at the beginning of the period and the proceeds from their exercise are assumed to have been used to purchase common shares at the average market price during the period. When a loss is incurred during the period, basic and diluted loss per share is the same as the exercise of stock options and share purchase warrants is considered to be anti-dilutive. As of October 31, 2024, the Company had 2,819,173 (2023 – 833,810, 2022- 26,419) potentially dilutive shares outstanding. n. The Company capitalizes certain legal and other third-party fees that are directly related to the Company’s in- process equity financing until such financing is consummated. After consummation of such equity financing, these costs are recorded as a reduction of the respective gross proceeds. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are written off to operating expenses. Where the financing includes both an equity and liability component, pro-rata issuance costs relating to the liability component are charged to the statement of operations. o. New and amended IFRS accounting standards that are effective for the current year i) Amendments to IAS 1 Presentation of Financial Statements— The IASB issued a narrow-scope amendment to IAS 1, in January 2020, to clarify that liabilities are classified as either current or non-current, depending on the rights that exist at the end of the reporting period. The amendment could affect the classification of liabilities, particularly for entities that previously considered management’s intentions to determine classification and for some liabilities that can be converted into equity. Inter alia, the amendment requires the following: Liabilities are classified as non-current if the entity has a substantive right to defer settlement for at least 12 months at the end of the reporting period. The amendment no longer refers to unconditional rights. The assessment determines whether a right exists, but it does not consider whether the entity will exercise the right. ’Settlement’ is defined as the extinguishment of a liability with cash, other economic resources or an entity’s own equity instruments. There is an exception for convertible instruments that might be converted into equity, but only for those instruments where the conversion option is classified as an equity instrument as a separate component of a compound financial instrument. The amendments are applied retrospectively for annual periods beginning on or after 1 January 2024, with early application permitted. The amendments had no significant impact on the consolidated financial statements. o. New and amended IFRS accounting standards that are effective for the current year (continued) ii) Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 Making Materiality Judgements - Disclosure of Accounting Policies The amendments change the requirements in IAS 1 with regard to disclosure of accounting policies. The amendments replace all instances of the term ’significant accounting policies’ with ‘material accounting policy information’. Accounting policy information is material if, when considered together with other information included in an entity’s financial statements, it can reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements. The supporting paragraphs in IAS 1 are also amended to clarify that accounting policy information that relates to immaterial transactions, other events or conditions is immaterial and need not be disclosed. Accounting policy information may be material because of the nature of the related transactions, other events or conditions, even if the amounts are immaterial. However, not all accounting policy information relating to material transactions, other events or conditions is itself material. The IASB has also developed guidance and examples to explain and demonstrate the application of the ‘four-step materiality process’ described in IFRS Practice Statement 2. The amendments are applied for annual periods beginning on or after January 1, 2023. p. New and revised IFRS Accounting Standards in issue but not yet effective i) IFRS 18 Presentation and Disclosures in Financial Statements IFRS 18 replaces IAS 1, carrying forward many of the requirements in IAS 1 unchanged and complementing them with new requirements. IFRS 18 introduces new requirements to: ● present specified categories and defined subtotals in the statement of profit or loss ● provide disclosures on management-defined performance measures (MPMs) in the notes to the financial statements ● improve aggregation and disaggregation. An entity is required to apply IFRS 18 for annual reporting periods beginning on or after 1 January 2027, with earlier application permitted. The amendments to IAS 7 and IAS 33, as well as the revised IAS 8 and IFRS 7, become effective when an entity applies IFRS 18. IFRS 18 requires retrospective application with specific transition provisions. The Company anticipates that the application of these amendments may have an impact on the consolidated financial statements in future periods.

Intangible Assets

Intangible Assets	12 Months Ended
	Oct. 31, 2024
Intangible Assets [Abstract]
Intangible Assets	3. Intangible Assets On May 4, 2021, the Company entered into an assignment agreement to acquire certain intellectual property including a patent for “Binge Behavior Regulators,” which has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S, and a patent for “Alcohol Beverage Substitute,” which has been approved for a European patent, with pending applications in the U.S., China and India. In consideration for the acquired intellectual property, the Company paid $160,000. The patents are amortized over their estimated remaining life of 14.6 years. The amortization expenses are presented under research and development expenses.

Leases

Leases	12 Months Ended
	Oct. 31, 2024
Leases [Abstract]
Leases	4. Leases On July 1, 2021, the Company entered into a lease agreement (“2021 Lease”) with Scisparc Ltd, a related party (“Scisparc”) and a third party for a total area of approximately 240m 2 On December 25, 2023, the Company entered into an agreement with SciSparc for the lease of office space in Tel Aviv, Israel, having a total area of approximately 240 square meters. The Company occupies approximately 120 square meters of the space for its offices. The Company’s base rent was ILS 23,300 per month (approximately $6,500) during the term of the lease. The lease liability was discounted using the Company’s estimated incremental borrowing rate of 10%. On March 31, 2024, the Company and SciSparc agreed to terminate the lease agreement prior to the initial term of the lease. As a result, the Company paid early termination fees of approximately $13,000 and paid approximately $3,000 to a broker. The loss upon early termination related to this transaction was recorded as general and administrative expenses within the Consolidated Statements of Operations and Comprehensive Loss. On June 13, 2024, the Company entered into an agreement with SciSparc for the lease of office space in Tel Aviv, Israel, having a total area of approximately 386 square meters. The Company occupies approximately 193 square meters of the space for its offices. The rental period is from April 1, 2024 to March 31, 2026. The Company’s base rent was ILS 12,500 per month (approximately $3,400) during the term of the lease. The lease liability was discounted using the Company’s estimated incremental borrowing rate of 10%. ROU Balance, October 31, 2023 $ - Addition 181,779 Early termination of office lease (88,562 ) Accumulated depreciation (39,023 ) Exchange rate differences (2,531 ) Balance, October 31, 2024 $ 51,663 Lease Balance, October 31, 2023 $ - Addition 181,779 Early termination of office lease (88,905 ) Lease payments (42,587 ) Interest expense 5,386 Exchange rate differences (2,531 ) Balance, October 31, 2024 $ 53,142 Amounts recognized in profit or loss Year ended October 31, 2024 Depreciation $ 39,023 Interest 5,386 $ 44,409

Short-Term Investments

Short-Term Investments	12 Months Ended
	Oct. 31, 2024
Short-term Investments [Abstract]
Short-term Investments	5. Short-term Investments October 31, Additions Disposals Changes in October 31, Polyrizon Ltd. – shares and warrants (1) $ - $ 350,400 $ - $ (61,012 ) $ 289,388 Xylo Technologies Ltd. – shares (2) 86,112 - (78,500 ) (7,612 ) - $ 86,112 $ 350,400 $ (78,500 ) $ (68,624 ) $ 289,388 October 31, Additions Disposals Changes in fair value October 31, Xylo Technologies Ltd. – shares (2) $ 193,750 $ - $ - $ (107,638 ) $ 86,112 (1) On October 30, 2024, the Company subscribed for 80,000 shares and 240,000 warrants (“Polyrizon Warrants”) of Polyrizon Ltd. (“Polyrizon”) in Polyrizon’s initial public offering on the Nasdaq at a cost of $350,400. Each Polyrizon Warrant can be exercised into one ordinary share of Polyrizon at an exercise price of $4.38 per share. The Polyrizon Warrants expire on October 29, 2029. The fair value of the Polyrizon Warrants as of October 31, 2024, was $178,988 based on the Block-Scholes option pricing model, using the following assumptions: risk-free rate of 4.28%, expected life of 5 years and volatility of 92%. See note 19a. (2) Pursuant to the Share Exchange Agreement with Xylo Technologies Ltd. (formerly known as Medigus Ltd.) (“Xylo”), on February 14, 2022, the Company received 27,778 ordinary shares of Xylo. The investment cost of the share was $501,938. During the year ended October 31, 2024, the Company sold all its remaining shares of Xylo, for total proceeds of $78,500 and recorded changes in fair value of $7,612.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Oct. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	6. Related Party Transactions a. Compensation to key management personnel (i) The compensation to key management personnel for employment services they provide to the Company is as follows: Year ended Year ended Year ended October 31, October 31, October 31, 2024 2023 2022 Officers: Payroll and other short-term benefits $ - $ - $ 32,533 Consulting fees 422,522 410,066 453,519 Share based compensation 185,843 124,808 772,786 $ 608,365 $ 534,874 $ 1,258,838 Directors: Directors’ fees and payroll $ 242,603 $ 182,261 $ 124,746 Share based compensation 296,728 121,981 43,485 $ 539,331 $ 304,242 $ 168,231 (ii) Balances with related parties October 31, October 31, 2024 2023 Amounts owed to officers $ 29,498 $ 29,666 Amounts owed to directors 19,464 12,767 $ 48,962 $ 42,433 b. On March 7, 2022, the Company signed an agreement with SciSparc Ltd (“SciSparc”), pursuant to which the Company and SciSparc agreed to cooperate in conducting a feasibility study using certain molecules developed by each party (the “Cooperation Agreement”). Certain of the Company’s officers and directors currently operate, manage or are engaged as officers and/or directors of SciSparc. In June 2023, the Company entered into a research agreement with the Hebrew University of Jerusalem to evaluate it’s and SciSparc’s combination treatment for obesity and metabolic syndrome. To date, the collaboration has resulted in the filing of nine patent applications. To the extent the parties determine to proceed to a commercial cooperation, they will enter into a joint venture where the parties share the economics and rights on a 50%-50% basis. To date, no determination has been made to pursue the joint venture and the development of the molecule remains in a very early stage. The Company incurred research and development expenses conducted within the framework of the Cooperation Agreement in the amount of $50,319, $141,409 and $194,205 for the years ended October 31, 2024, 2023 and 2022, respectively. As of October 31, 2024, $131,839 is owed to the Company by SciSparc (As of October 31, 2023- $136,002). c. The Company shares office space with SciSparc and participates in the payment of office expenses– see Note 4.

Derivative Warrant Liabilities

Derivative Warrant Liabilities	12 Months Ended
	Oct. 31, 2024
Derivative Warrant Liabilities [Abstract]
Derivative warrant liabilities	7. Derivative warrant liabilities a. On April 6, 2023, the Company issued 4,505,718 warrants in connection with its April 2023 Public Offering (“April 2023 Warrants”). The warrants include a cashless exercise provision and repricing adjustments for offerings at a price lower than the existing exercise price of the warrants, stock splits, reclassifications, subdivisions, and other similar transactions (“April 2023 Warrant Adjustments”) and therefore, these warrants were recorded at their fair value as a derivative liability and the time of the grant and are revalued at the end of each reporting period. The number of warrants does not change, however, the number of warrant shares issued may change, subject to the adjustment noted above. On January 21, 2024, following the January 2024 Public Offering, which included the offering of common shares at a price lower than the exercise price of the April 2023 Warrants, the exercise price of the April 2023 Warrants was reduced to $1.077, and each April 2023 Warrant became exercisable into 0.724 common shares of the Company. For further details of the ratio of warrant shares issuable and outstanding in relation to the April 2023 Warrants, see detailed table in note 9. During the period between November 29, 2023 and December 5, 2023, 2,729,394 April 2023 Warrants were exercised into 652,521 common shares. During the period between March 8, 2024 and March 22, 2024, 27,973 April 2023 Warrants were exercised into 20,245 common shares. On June 28, 2024, 156,098 April 2023 Warrants were exercised into 112,975 common shares. On August 12, 2024, 64,104 April 2023 Warrants were exercised into 46,395 common shares. b. On September 18, 2023, the Company issued 7,500,000 warrants in connection with its September 2023 Public Offering (“September 2023 Warrants”). The warrants include a cashless exercise provision and repricing adjustments for offerings at a price lower than the existing exercise price of the warrants, stock splits, reclassifications, subdivisions, and other similar transactions (“September 2023 Warrant Adjustments”) and therefore, these warrants were recorded at their fair value as a derivative liability at the time of the grant and are revalued at the end of each reporting period. The number of warrants does not change, however, the number of warrant shares issued may change, subject to the adjustment noted above. On January 21, 2024, following the January 2024 Public Offering, which included the offering of common shares at a price lower than the exercise price of the September 2023 Warrants, the exercise price of the September 2023 Warrants was reduced to $1.077, and each September 2023 Warrant became exercisable into 0.288 common shares of the Company. For further details of the ratio of warrant shares issuable and outstanding in relation to the September 2023 Warrants, see detailed table in note 9. During the period between November 29, 2023 and December 5, 2023, 4,602,916 September 2023 Warrants were exercised into 409,667 common shares. During the period between February 23, 2024 and March 22, 2024, 281,910 September 2023 Warrants were exercised into 81,469 common shares. On June 28, 2024, 182,144 September 2023 Warrants were exercised into 54,877 common shares. On August 12, 2024, 80,526 September 2023 Warrants were exercised into 23,197 common shares. c. On January 16, 2024, the Company issued 1,500,000 warrants with an exercise price of $1.60 per warrant in connection with its January 2024 Public Offering (“January 2024 Warrants”). Each warrant includes a cashless exercise provision and repricing adjustments for offerings at a price lower than the existing exercise price of the warrants, stock splits, reclassifications, subdivisions, and other similar transactions (“January 2024 Warrant Adjustments”) and therefore, these warrants were recorded at their fair value as a derivative liability at the time of the grant and are revalued at the end of each reporting period. On February 23, 2024, 30,200 January 2024 Warrants were exercised into 30,200 common shares. During the period between June 20, 2024 and July 16, 2024, 138,320 January 2024 Warrants were exercised into 138,320 common shares. d. During the year ended October 31, 2024, the Company recorded a gain on the revaluation of the total derivative warrant liabilities of $707,802 in the Consolidated Statements of Operations and Comprehensive Loss. e. The binomial model was used to measure the derivative warrant liability with the following assumptions: October 31, Share Price $ 1.39 Exercise Price $ 1.077-$1.60 Expected life 3.43-4.21 years Risk-free interest rate 4.13-4.14 % Dividend yield 0.00 % Expected volatility 143.59-147.59 % Expected volatility was determined by calculating the historical volatility of the Company’s share price and comparison companies’ standard deviation over the previous 4.21 years. The expected life used in the model has been adjusted, based on management’s best estimate, for the effects of no transferability, exercise restrictions, and behavioral considerations. f. The following table presents the changes in the warrant liability during the period: Balance as of November 1, 2022 $ - Issuance of April 2023 Warrants 1,771,208 Issuance of September 2023 Warrants 923,225 Exercise of warrants (574,040 ) Changes in fair value of warrants 2,189,986 Balance as of October 31, 2023 $ 4,310,379 Issuance of January 2024 Warrants 480,004 Exercise of warrants (562,879) Changes in fair value of warrants (707,802) Balance as of October 31, 2024 $ 3,519,702

Share Capital

Share Capital	12 Months Ended
	Oct. 31, 2024
Share Capital [Abstract]
Share Capital	8. Share Capital a. The Company’s authorized share capital is an unlimited number of common shares without par value share. As of October 31, 2024, 4,265,186 (as of October 31, 2023 – 607,337) common shares were issued and outstanding. b. On September 30, 2022 and November 28, 2023, the Company effected 1-for-30 share consolidations of its issued and outstanding common shares. All share amounts and instruments convertible into common shares prior to the date of the reverse share splits have been retroactively restated for all periods presented. c. Share transactions during the year ended October 31, 2024: (i) On November 6, 2023, 45 common shares with a fair value of $117 were issued to providers of investor services in payment of services. (ii) Between December 1, 2023 and December 11, 2023, April 2023 Warrants and September 2023 Warrants were exercised into 1,062,188 common shares, resulting in gross proceeds of $3,498,032. (iii) On January 16, 2024, the Company completed a registered direct offering and concurrent private placement of (i) 1,468,000 Common Shares, (ii) 32,000 pre-funded warrants to purchase 32,000 Common Shares and (iii) 1,500,000 unregistered common warrants to purchase 1,500,000 Common Shares. The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per Common Share and will not expire until exercised in full. The unregistered common warrants have an exercise price of $1.60 per Common Share (after giving effect to adjustments and subject to further adjustments as set forth therein), are immediately exercisable, and expire five years from the date of issuance. These warrants include a cashless exercise provision and repricing provisions, under certain circumstances (“the January 2024 Offering”). The gross proceeds from the January 2024 Offering were approximately $2.4 million before deducting estimated offering expenses. Net proceeds from the offering were $1,824,773. On January 17, 2024, the pre-funded warrants were exercised. (iv) On February 19, 2024, 44 common shares with a fair value of $68 were issued to providers of investor services in payment of services. (v) During the period between February 26, 2024 and March 26, 2024, April 2023 Warrants, September 2023 Warrants and January 2024 Warrants were exercised into 131,914 common shares, for gross proceeds of $157,918. (vi) On April 3, 2024, 9,000 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $11,935 at the time of issuance. (vii) On May 9, 2024, 88 common shares with a fair value of $127 were issued to providers of investor services in payment of services. (viii) On June 17, 2024, 162,970 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $243,003 at the time of issuance. (ix) During the period between June 20, 2024 and July 16, 2024, April 2023 Warrants, September 2023 Warrants and January 2024 Warrants were exercised into 306,172 common shares, for gross proceeds of $402,206. (xi) On July 4, 2024, 64,617 common shares with a fair value of $98,218 were issued to providers of investor services in payment of services. (xii) During the period between July 4, 2024 and July 8, 2024, 134,868 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $256,252 at the time of issuance. (xiii) On August 12, 2024, April 2023 Warrants and September 2023 Warrants were exercised into 69,592 common shares, for gross proceeds of $74,999. (xiv) During the period between September 5, 2024 and September 19, 2024, 22,500 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $30,645 at the time of issuance. (xv) On October 31, 2024, 193,851 common shares with a fair value of $269,453 were issued to providers of investor services in payment of services. d. Share transactions during the year ended October 31, 2023: (i) On November 14, 2022, the Company completed an underwritten public offering of 38,462 common shares at a price to the public of $195.00 per share, for aggregate gross proceeds of $7.5 million, prior to deducting underwriting discounts and offering expenses. The offering closed on November 17, 2022. Net proceeds from the offering were $6,363,906. In addition, the Company granted Aegis Capital Corp. (“Aegis”), who acted as the underwriters for the deal, a 45-day option to purchase up to 5,769 additional common shares, equal to 15% of the number of common shares sold in the offering solely to cover over-allotments, if any (“Over-Allotment”). The public purchase price per additional common share would have been $195.00 per share. The Over-Allotment was not exercised. Aegis received 1,923 underwriter warrants, each such warrant entitling the agents to receive one common share upon payment of $243.75 per share, exercisable six months after the commencement of sales of this offering and expiring on a date which is no more than five years after the commencement of sales of the offering. The fair value of the underwriter warrants of $337,579 were accounted for as an issuance cost within the share-based payment reserve. The fair value of the underwriters warrants was estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Risk-free interest rate 1.43 % Expected life (in years) 5 Expected volatility 150 % In connection with the offering, the Company’s common shares were approved for listing on the Nasdaq and began trading on the Nasdaq (in addition to the CSE) under the symbol “CMND” on November 15, 2022. Following the public offering and pursuant to the Xylo SPA (see note 8e(iii)), Xylo was entitled to receive 1,494 common shares and 75 warrants pursuant to an anti-dilution clause included in the agreement signed between the Company and Xylo on June 29, 2022. The anti-dilution feature was recorded as a derivative liability as of October 31, 2022. On May 23, 2023, the Company issued the 1,494 common shares and 75 warrants to Xylo. The fair value of the issuance ($296,845) was recorded in shareholder equity against the extinguishment of the derivative liability. (ii) On January 16, 2023, 161 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $39,975 at the time of issuance. On February 22, 2023, 400 common shares were issued in respect of fully vested RSU’s that had been fully vested. The RSU’s had a fair value of $110,096 at the time of issuance. (iii) On April 6, 2023, the Company completed an underwritten public offering of 103,249 common shares at a price to the public of $23.40 per share and pre-funded warrants to purchase 46,942 common shares at a price to the public of $23.37 per pre-funded warrant (“Pre-Funded Warrants”), for aggregate gross proceeds of $3.5 million (the “April 2023 Public Offering”). The Pre-Funded Warrants were exercisable at $0.03 into one common share, and all the Pre-Funded Warrants were exercised by April 30, 2023. In addition, each April 2023 Public Offering shareholder and each Pre-Funded Warrant holder received a common warrant, which was immediately exercisable, will expire five years from the date of issuance and have an exercise price of $23.40 per common share (“April 2023 Public Offering Warrant”). The April 2023 Public Offering warrants include a cashless exercise provision and repricing provisions under certain circumstances, that also includes a potential change in the number of shares to be issued for each warrant depending on the change in the exercise price of the warrant. Net proceeds from the offering were $2,936,079. (iv) On May 23, 2023, 239 common shares with a fair value of $27,965 were issued to consultants and 1,494 common shares with a fair value of $110,000 were issued to providers of investor services in respect of services. (v) On June 1, 2023, 245 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $48,194 at the time of issuance. (vi) On July 10, 2023, 597 common shares with a fair value of $10,000 were issued to providers of investor services in respect of services. (vii) On August 28, 2023, 585 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $65,143 at the time of issuance and 44 common shares with a fair value of $607 were issued to providers of investor services in respect of services. (viii) On September 18, 2023, the Company completed an underwritten public offering of 225,833 common shares at a price to the public of $9.00 per share and pre-funded warrants to purchase 24,167 common shares at a price to the public of $8.97 per pre-funded warrant (“Pre-Funded Warrants”), for aggregate gross proceeds of $2.25 million (the “September 2023 Public Offering”). The Pre-Funded Warrants were exercisable at $0.03 into one common share, and all the Pre-Funded Warrants were exercised by September 30, 2023. In addition, each September 2023 Public Offering shareholder and each Pre-Funded Warrant holder received a common warrant, which was immediately exercisable, will expire five years from the date of issuance and have an exercise price of $9.00 per common share (“September 2023 Public Offering Warrant”). The September 2023 Public Offering warrants include a cashless exercise provision and repricing provisions under certain circumstances that also includes a potential change in the number of shares to be issued for each warrant depending on the change in the exercise price of the warrant. Net proceeds from the offering were $1,814,193. (ix) During the period between October 17, 2023 and October 20, 2023, 784,584 April 2023 Warrants with a fair value of $574,040 were exercised into 119,433 common shares. e. Share transactions during the year ended October 31, 2022: (i) On November 26, 2021, the Company issued 44 common shares with a fair value of $21,100 to the Chief Science Officer (“CSO”) of the Company. (ii) On February 14, 2022, the Company issued 45 common shares with a fair value of $17,584 to the CSO. (iii) On February 14, 2022, the Company completed a share purchase agreement with Xylo, whereby the Company issued a total of 2,208 units to Xylo in consideration for $750,000 (“Cash Financing”) and 27,778 common shares of Xylo (“Share Exchange”). Each unit is comprised of one common share and one warrant, with each warrant exercisable for a period of 18 months at CAD$60.00 per share (the “Xylo SPA”). The Xylo SPA contains certain anti-dilution provisions. Pursuant to the Cash Financing, the Company issued 1,325 units at $720.00 per unit for proceeds of $698,897. In connection with the Cash Financing, the Company incurred finder’s fees of $69,890, which have been charged to the statement of changes in equity. Pursuant to the Share Exchange, the Company issued 883 units with a fair value of $455,487, consisting of common shares with a fair value of $372,745 and warrants with a fair value of $82,742. The fair value of the warrants was determined using the Black-Scholes option pricing model with the following assumptions: Risk-free rate of 1.43%, expected life of 1.5 years, and volatility of 107.46%. In connection with the Share Exchange, the Company incurred finder’s fees of $50,000, which were allocated to the base cost of the shares in Xylo. On June 29, 2022, the Company signed an amendment to the Xylo Agreement (“Xylo Amended Agreement”), pursuant to which, in the event of an initial public offering, Xylo would receive, in respect of the Cash Financing, for no additional consideration, the number of shares necessary to maintain an ownership percentage of the Company’s shares equal to the level of ownership it had at the time of the Xylo Agreement. As of October 31, 2022, the Company recorded the fair value of this derivative financial liability in the amount of $290,569 as a current liability.

Warrants

Warrants	12 Months Ended
	Oct. 31, 2024
Warrants [Abstract]
Warrants	9. Warrants The following table summarizes the changes in the Company’s warrants: Number of Historic weighted Balance, October 31, 2022 19,763 576.66 Issuance of underwriter warrants 1,923 243.75 Issuance of April 2023 warrants (*) 4,505,718 5.124 Issuance of September 2023 warrants (*) 7,500,000 9.00 Issuance of Xylo warrants 75 1,297.67 Expiration of warrants (11,430 ) 922.98 Exercise of warrants (784,584 ) 5.124 Balance, October 31, 2023 11,231,465 $ 7.90 Number of shares to be issued from the exercise of these warrants, October 31, 2023 826,781 Balance, October 31, 2023 11,231,465 $ 7.90 Issuance of January 2024 warrants (Note 7c) (*) 1,500,000 1.60 Exercise of warrants (8,293,585 ) 2.62 Expiration of warrants (8,333 ) 98.43 Balance, October 31, 2024 (**) 4,429,547 $ 1.57 Number of shares to be issued from the exercise of these warrants 2,549,311 (*) These warrants include a cashless exercise provision and repricing provisions under certain circumstances, that also includes a potential change in the number of shares to be issued for each warrant depending on the change in the exercise price of the warrant. See table below for number of shares to be issued from the exercise of warrants. (**) See note 19(b) regarding the exercise of warrants. As of October 31, 2024, the following share purchase warrants were outstanding: Number of Number of shares Exercise price per Exercise price per Expiry date 1,923 1,923 C$ 339.20 $ 243.75 November 17, 2027 743,565 538,150 $ 1.077 $ 1.077 April 5, 2028 75 75 C$ 1,800 $ 1,293.48 November 23, 2024 2,352,504 677,683 $ 1.077 $ 1.077 September 17, 2028 1,331,480 1,331,480 $ 1.60 $ 1.60 January 15, 2029 4,429,547 2,549,311

Stock Options

Stock Options	12 Months Ended
	Oct. 31, 2024
Stock Options [Abstract]
Stock Options	10. Stock Options a. On November 14, 2023, the shareholders of the Company approved the Omnibus Equity Incentive Plan, or the Omnibus Plan. Pursuant to the Omnibus Plan, the Company is authorized to grant options or restricted share units (“RSUs) to officers, directors, employees and consultants enabling them to acquire, together with” Options”, “Awards” or “Stock Options” as defined, up to 20% of the Company’s issued and outstanding Common Shares (after taking into account existing awards from the Company’s 2021 stock option plan). The Awards can be granted for a maximum of 10 years and vest as determined by the Board. The maximum number of common shares reserved for issuance in any 12-month period to a related party consultant may not exceed 5% of the issued and outstanding common shares at the date of the grant (and may not exceed 15% in total, to all related parties). The maximum number of common shares reserved for issuance in any 12-month period to any investor relations service provider may not exceed 2% of the issued and outstanding common shares at the date of the grant. b. The following table summarizes the changes in the Company’s stock options for the years ended October 31, 2024 and October 31, 2023: Number of Weighted Weighted Outstanding, October 31, 2022 5,254 C$ 613.5 $ 450.64 Granted (i, ii, iii) 334 442.22 318.81 Outstanding, October 31, 2023 5,588 C$ 603.12 $ 434.82 Expired (67 ) 720.00 533.14 Outstanding, October 31, 2024 5,521 C$ 601.71 $ 432.38 Exercisable, October 31, 2024 5,351 C$ 603.50 $ 433.67 i) On May 23, 2023, the Company granted 61 stock options to a consultant of the Company. The options are exercisable at $227.09 (CAD$315.00) per share. The options expire on May 23, 2033. ii) On June 26, 2023, the Company granted 223 stock options to a consultant of the Company. The 156 options are exercisable at $363.35 (CAD$504.00) per share and the 67 options are exercisable at $519.07 (CAD$720.00) per share. The options expire on June 26, 2033. iii) On July 6, 2023, the Company granted 50 stock options to a consultant of the Company. The options are exercisable at $23.40 per share. The options expire on July 6, 2033. c. Additional information regarding stock options outstanding as of October 31, 2024, is as follows: Outstanding Exercisable Number of Weighted Weighted Weighted Number of Weighted Weighted 533 1.57 C$ 166.50 $ 119.65 533 C$ 166.50 $ 119.65 978 7.26 504.00 362.17 920 504.00 362.17 1,166 1.56 675.00 485.05 1,166 675.00 485.05 200 4.49 702.00 504.46 200 702.00 504.46 133 1.88 747.00 536.79 133 747.00 536.79 422 7.11 612.00 439.78 422 612.00 439.78 1,044 7.26 720.00 517.39 957 720.00 517.39 667 1.67 756.00 543.26 667 756.00 543.26 111 7.11 900.00 646.74 111 900.00 646.74 61 8.56 315.00 226.36 61 315.00 226.36 156 8.66 504.00 362.17 156 504.00 362.17 50 8.68 32.56 23.40 25 32.56 23.40 5,521 4.65 C$ 601.71 $ 432.38 5,351 C$ 603.50 $ 433.67 The fair value of stock options previously granted to certain consultants for ongoing services measured during the period have been estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Year ended October 31, 2024 2023 Risk-free interest rate 4.22 % 4.10 % Expected life (in years) 4.61 5.61 Expected volatility 125.77-133.62 % 140.41-160.81 % Expected volatility was determined by calculating the historical volatility of the comparison companies’ share price over the previous 8.6 years. The expected life used in the model has been adjusted, based on management’s best estimate, for the effects of no transferability, exercise restrictions, and behavioral considerations. d. The portion of the total fair value of stock options expensed during the year ended October 31, 2024, was $79,005 (2023 - $221,625) which was recorded as share-based compensation expense.

Restricted Share Units

Restricted Share Units	12 Months Ended
	Oct. 31, 2024
Restricted Share Units [Abstract]
Restricted Share Units	11. Restricted Share Units a. On August 4, 2021, the Company approved an RSU plan, which is designed to provide certain directors, officers, employees, and consultants of the Company with the opportunity to acquire RSU’s of the Company. Each unit is equivalent in value to a common share and upon vesting results in the holder thereof being issued, at the discretion of the Board, either (i) a common share, or (ii) an amount of cash equal to the fair market value of a common share. b. The following table summarizes the changes in RSUs: Number of Weighted Weighted Balance, October 31, 2022 1,407 $ 375.54 $ 273.42 Granted 2,200 55.97 41.63 Exercised (1,391 ) 246.64 189.37 Balance, October 31, 2023 2,216 $ 138.55 $ 96.06 Granted (i) 591,460 1.86 1.36 Exercised (329,338 ) 2.22 1.65 Balance, October 31, 2024 264,338 $ 2.55 $ 1.80 (i) During the year ended October 31, 2024, the Company issued 591,460 RSU’s to consultants, directors and officers. The RSU’s vested with a fair value of $804,962 (2023-$91,589).

Financial Instruments and Risk

Financial Instruments and Risk Management	12 Months Ended
	Oct. 31, 2024
Financial Instruments and Risk Management [Abstract]
Financial Instruments and Risk Management	12. Financial Instruments and Risk Management a. Fair Values Fair value measurements are classified using a fair value hierarchy that reflects the significance of inputs used in making the measurements. The fair value hierarchy has the following levels: ● Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities; ● Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and ● Level 3 - valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs). Assets and liabilities measured at fair value on a recurring basis were presented on the Company’s statement of financial position as of October 31, 2024, as follows: Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment- shares $ 110,400 $ – $ – $ 110,400 Short-term investment- Polyrizon Warrants – – 178,988 178,988 Derivative warrant liabilities – – 3,519,702 3,519,702 Assets and liabilities measured at fair value on a recurring basis were presented on the Company’s statement of financial position as of October 31, 2023, as follows: Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment $ 86,112 $ – $ – $ 86,112 Derivative warrant liabilities – – 4,310,379 4,310,379 The fair value of other assets and liabilities, which include cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities and amounts due to related parties, approximate their carrying values due to the relatively short-term maturity of these instruments. b. Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit loss by placing its cash with high credit quality financial institutions. The carrying amount of financial assets represents the maximum credit exposure. c. Foreign Exchange Rate Risk Foreign currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company is exposed to foreign currency risk to the extent that monetary assets and liabilities are denominated in a foreign currency. The Company’s subsidiary operates in Israel and has certain monetary financial instruments denominated in New Israeli Shekel and CAD. The Company has not entered into foreign exchange rate contracts to mitigate this risk. The following table indicates the impact of foreign currency exchange risk on net working capital as of October 31, 2024. The table below also provides a sensitivity analysis of a 10% strengthening of the foreign currency against functional currencies identified which would have increased (decreased) the Company’s net loss by the amounts shown in the table below. A 10% weakening of the foreign currency against the functional currencies would have had the equal but opposite effect as of October 31, 2024. Cash and cash equivalents $ 137,666 Amounts receivable 49,038 Accounts payable and accrued liabilities (192,971 ) Due to related parties (38,962 ) Total foreign currency financial assets and liabilities $ (45,229 ) Impact of a 10% strengthening or weakening of foreign exchange rate $ (4,523 ) d. Interest Rate Risk Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The fair value of the derivative warrant liabilities can fluctuate depending on the fluctuation in the risk-free interest rate. e. Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company’s objective to managing liquidity risk is to ensure that it has sufficient liquidity available to meet its liabilities when due. The Company relies on raising debt or equity financing in a timely manner. The following amounts are the contractual maturities of financial liabilities as of October 31, 2024 and 2023: October 31, 2024 Total Within Within Accounts payable and accrued liabilities $ 526,056 $ 526,056 $ – Due to related parties 48,962 48,962 – Lease liability 53,142 36,726 16,416 $ 628,160 $ 611,744 $ 16,416 October 31, 2023 Total Within Within Accounts payable and accrued liabilities $ 617,004 $ 617,004 $ – Due to related parties 42,433 42,433 – $ 659,437 $ 659,437 $ –

Capital Management

Capital Management	12 Months Ended
	Oct. 31, 2024
Capital Management [Abstract]
Capital Management	13. Capital Management The Company manages its capital to maintain its ability to continue as a going concern and to provide returns to shareholders and benefits to other stakeholders. The capital structure of the Company consists of cash and equity comprised of issued share capital and share premium, warrants and share-based payment reserve. The Company manages its capital structure and makes adjustments to it in light of economic conditions. The Company, upon approval from its Board, will balance its overall capital structure through new share issuances or by undertaking other activities as deemed appropriate under the specific circumstances. The Company is not subject to externally imposed capital requirements and the Company’s overall strategy with respect to capital risk management remains unchanged from the year ended October 31, 2024.

Commitments

Commitments	12 Months Ended
	Oct. 31, 2024
Commitments [Abstract]
Commitments	14. Commitments a. On January 15, 2024, the Company entered into a license agreement with BIRAD, the research and development company of Bar-Ilan University, which provides to the Company with an exclusive, perpetual, worldwide and sublicensable license to use the joint patent that the Company has with BIRAD to further develop, manufacture and commercialize products for innovative treatment of cocaine addiction (“the BIRAD License Agreement”). According to the BIRAD License Agreement, the Company shall pay BIRAD royalties at the rate of 1.5% of net sales, as well as certain fees in the case of sublicenses or an “exit” event, all subject to the terms as described in the BIRAD License Agreement. The Company will also pay BIRAD different payments when reaching several milestones. b. On March 19, 2024, the Company entered into a License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, which provides to the Company with an exclusive, perpetual, worldwide and sublicensable license to use to Yissum’s patent titled “psychedelic compounds, methods of their preparation and uses thereof” to further develop, manufacture, and commercialize innovative compounds targeted at treating post-traumatic stress disorder and other health conditions (the “Yissum PTSD License Agreement”). According to the Yissum PTSD License Agreement, the Company is required to pay Yissum annual maintenance fees ranging from $25,000 to $50,000 beginning of the fifth anniversary of the effective date of the Yissum PSTD License Agreement, and royalties at the rate of 3.0% of net sales, as well as certain fees in the case of sublicensing or an exit event, all subject to the terms as described in the Yissum PTSD License Agreement. The Company will also pay Yissum different payments when reaching several milestones. All right, title and interest in the patent (the Licensed Patent as defined in the Yissum PSTD License Agreement) vest solely in Yissum, and the Company shall hold and make use of the license granted. Subject to such Yissum’s ownership rights, all rights in results of the Company’s development shall be solely owned by the Company. c. On March 31, 2024, the Company entered into a License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, which provides to the Company with an exclusive, perpetual, worldwide and sublicensable license to use Yissum’s patent “psychoactive compounds, methods of their preparation and uses thereof in the treatment of mental disorders” to further develop, manufacture, and commercialize innovative compounds targeted at Generation 3.0 psychedelic compounds for the treatment of mental disorders (the “Yissum Psychedelic License Agreement). According to the Yissum Psychedelic License Agreement, the Company is required to pay Yissum annual maintenance fees ranging from $25,000 to $50,000 beginning of the fifth anniversary of the effective date of the Yissum Psychedelic License Agreement, and the Company shall pay Yissum royalties at the rate of 3.0% of net sales, as well as certain fees in the case of sublicenses or an exit event, all subject to the terms as described in the Yissum Psychedelic License Agreement. The Company will also pay Yissum different payments when reaching several milestones. All right, title and interest in the patent (the Licensed Patent as defined in the Yissum Psychedelic License Agreement) vest solely in Yissum, and the Company shall hold and make use of the license granted. Subject to such Yissum’s ownership rights, all rights in results of the Company’s development shall be solely owned by the Company. d. In respect to the Company’s lease commitment, refer to Note 4.

Segmented Information

Segmented Information	12 Months Ended
	Oct. 31, 2024
Segmented Information [Abstract]
Segmented Information	15. Segmented Information As of October 31, 2024, the Company has one operating segment, research and development of psychedelic medicine, which takes place primarily in Israel.

Income Taxes

Income Taxes	12 Months Ended
	Oct. 31, 2024
Income Taxes [Abstract]
Income Taxes	16. Income Taxes Tax rates applicable to the Company: The combined Canadian federal and provincial statutory income tax rate is 27% for years ended October 31, 2024, 2023 and 2022 and the Israeli statutory corporate tax rate was 23% in 2024, 2023 and 2022. The tax effect (computed by applying the Canadian federal and provincial statutory rate) of the significant differences, which comprise deferred income tax assets and liabilities, are as follows: 2024 2023 2022 Canadian statutory income tax rate 27 % 27 % 27 % Income tax recovery at statutory rate (1,316,712 ) (2,322,936 ) (1,861,476 ) Tax effect of: Items not deductible for tax purposes (20,556 ) 223,809 335,494 Over provided in prior years (384,109 ) (19,674 ) - Tax rate difference for foreign jurisdiction (5,365 ) 10,715 56,175 Change in unrecognized deferred income tax assets 2,104,708 2,125,459 1,499,666 Income tax provision 377,966 17,372 29,859 As of October 31, 2024, the Company has Canadian non-capital losses carried forward of $20,281,000, which is available to offset future years’ taxable income in Canada. These losses expire as follows: $ 2037 5,000 2038 73,000 2039 71,000 2040 169,000 2041 1,142,000 2042 4,716,000 2043 8,678,000 2044 5,427,000 20,281,000 Deferred tax assets have not been recognized in respect of these items because it is not probable that future taxable profit will be available against which the Company can utilize the benefits therefrom.

General and Administrative Expe

General and Administrative Expenses	12 Months Ended
	Oct. 31, 2024
General and Administrative Expenses [Abstract]
General and Administrative Expenses	17. General and Administrative Expenses Year ended Year ended Year ended October 31, October 31, October 31, 2024 2023 2022 Professional fees $ 1,998,625 $ 2,210,795 $ 1,093,871 Investor relations 440,041 1,565,970 473,106 Share-based compensation (Notes 6, 10 and 11) 1,119,041 243,717 946,324 Consulting fees (Note 6) 131,769 96,421 192,448 Insurance 329,278 364,059 149,537 Transfer agent and regulatory fees 190,397 171,439 86,605 Depreciation of ROU asset 39,023 35,381 60,665 Salaries and benefits (Note 6) 57,340 37,838 92,296 Office and miscellaneous 55,538 31,670 68,016 Depreciation of property and equipment 1,065 1,915 7,572 Total general and administrative $ 4,362,117 $ 4,759,205 $ 3,170,440

Research and Development, Net

Research and Development, Net	12 Months Ended
	Oct. 31, 2024
Research and Development, Net [Abstract]
Research and Development, net	18. Research and Development, net Year ended Year ended Year ended October 31, October 31, October 31, 2024 2023 2022 Research and preclinical studies $ 747,026 $ 1,159,147 $ 2,380,942 Salaries, regulatory, professional and other expenses 542,615 469,667 666,125 Share-based compensation (Notes 6, 10 and 11) 132,502 45,870 213,299 Reimbursements (Note 6) (50,319 ) (141,409 ) (194,205 ) Amortization of intangible assets 10,984 10,954 14,830 Total research and development, net $ 1,382,808 $ 1,544,229 $ 3,080,991

Subsequent Events

Subsequent Events	12 Months Ended
	Oct. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	19. Subsequent Events a. During November 2024, the Company sold all the shares of Polyrizon, for total proceeds of $82,961. b. During the period between December 13, 2024 and December 26, 2024, April 2023 Warrants, September 2023 Warrants and January 2024 Warrants, were exercised into 310,388 common shares, for gross proceeds of $441,577.

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Oct. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Oct. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	We operate in the pharmaceutical sector, which is subject to various cybersecurity risks that could adversely affect our business. We recognize the critical importance of developing, implementing, and maintaining cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our data. We currently have security measures in place to protect and prevent data loss and other security breaches. Our network infrastructure was designed with cybersecurity in mind, incorporating a range of critical components such as firewalls, intrusion detection and prevention systems, virtual private networks (VPNs), and secure Wi-Fi access points. Additionally, strong authentication mechanisms, encryption protocols, and robust monitoring tools are essential elements for ensuring a secure network infrastructure. These components work together to protect against unauthorized access, data breaches, malware attacks, and other cybersecurity threats. Our external information technology consultant is responsible for day-to-day assessment and management of risks from cybersecurity threats, including the prevention, mitigation, detection, and remediation of cybersecurity incidents. Our external information technology consultant offers expertise in regulatory compliance, helping us ensure that our security measures align with industry standards and legal requirements. Our external information technology consultant is experienced in operating a company which offers cybersecurity services. Our external information technology consultant regularly monitors our systems to detect cybersecurity incidents or risks. The Board is responsible for oversight of risks from cybersecurity threats in conjunction with management. The Board receives reports and updates from management with respect to the management of risks from cybersecurity threats. Such reports cover the Company’s information technology security program, including its current status, capabilities, objectives and plans, as well as the evolving cybersecurity threat landscape. The Board takes into consideration such reports and updates into its overall risk assessment of the Company. We also have policies and procedures to oversee and identify the risks from cybersecurity threats associated with our use of third-party service providers. When engaging with vendors or partners, we prioritize those who demonstrate robust cybersecurity measures and a strong commitment to protecting sensitive data. To mitigate risks associated with third-party providers, we incorporate specific cybersecurity requirements into contracts and service level agreements. These agreements outline expectations regarding data protection, access controls, incident reporting, and compliance monitoring. Furthermore, we implement other mechanisms to enhance security when working with third-party providers, including implementing two-factor authentication. By implementing these measures, we aim to minimize the cybersecurity risks associated with third-party service providers and ensure the protection of our organization’s assets and data.
Cybersecurity Risk Role of Management [Text Block]	Our external information technology consultant is responsible for day-to-day assessment and management of risks from cybersecurity threats, including the prevention, mitigation, detection, and remediation of cybersecurity incidents. Our external information technology consultant offers expertise in regulatory compliance, helping us ensure that our security measures align with industry standards and legal requirements. Our external information technology consultant is experienced in operating a company which offers cybersecurity services. Our external information technology consultant regularly monitors our systems to detect cybersecurity incidents or risks.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	Our external information technology consultant offers expertise in regulatory compliance, helping us ensure that our security measures align with industry standards and legal requirements.
Cybersecurity Risk Board of Directors Oversight [Text Block]	The Board is responsible for oversight of risks from cybersecurity threats in conjunction with management. The Board receives reports and updates from management with respect to the management of risks from cybersecurity threats. Such reports cover the Company’s information technology security program, including its current status, capabilities, objectives and plans, as well as the evolving cybersecurity threat landscape. The Board takes into consideration such reports and updates into its overall risk assessment of the Company.
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	We also have policies and procedures to oversee and identify the risks from cybersecurity threats associated with our use of third-party service providers. When engaging with vendors or partners, we prioritize those who demonstrate robust cybersecurity measures and a strong commitment to protecting sensitive data. To mitigate risks associated with third-party providers, we incorporate specific cybersecurity requirements into contracts and service level agreements. These agreements outline expectations regarding data protection, access controls, incident reporting, and compliance monitoring. Furthermore, we implement other mechanisms to enhance security when working with third-party providers, including implementing two-factor authentication. By implementing these measures, we aim to minimize the cybersecurity risks associated with third-party service providers and ensure the protection of our organization’s assets and data.
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	false
Cybersecurity Risk Management Third Party Engaged [Flag]	true

Material Cybersecurity Incident

Material Cybersecurity Incident Disclosure	12 Months Ended
	Oct. 31, 2024
Material Cybersecurity Incident [Line Items]
Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]	As of the date of this report, we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition. Item 3.D Risk Factors—General Risk Factors—Our business and operations might be adversely affected by security breaches, including any cybersecurity incidents.”

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Oct. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	a. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) on a going concern basis. These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Clearmindmed Ltd. and Clearmind Labs Corp. (inactive). All inter-company balances and transactions have been eliminated on consolidation. These consolidated financial statements have been prepared on a historical cost basis, except for financial assets and liabilities (including derivatives) which are presented at fair value through profit or loss (“FVTPL”) and are presented in U.S. dollars, which is the Company’s functional currency as of November 1, 2022.
Significant Accounting Estimates and Judgments	b. Significant Accounting Estimates and Judgments The preparation of consolidated financial statements in accordance with IFRS requires management to make judgments, estimates, and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Significant Estimates Share-based Compensation Fair values are determined using the Black-Scholes option pricing model. Estimating fair value requires determining the most appropriate valuation model for a grant of equity instruments, which is dependent on the terms and conditions of the grant. Option-pricing models require the use of highly subjective estimates and assumptions including the expected stock price volatility. Changes in the underlying assumptions can materially affect the fair value estimates and, therefore, existing models do not necessarily provide reliable measurement of the fair value of the Company’s stock options. Derivative Warrant Liabilities and Assets The Company analyses warrants issued to determine whether they meet the classification as liabilities or equity. Derivative warrant liabilities and assets are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations. The Company uses a fair valuation specialist to estimate the value of these instruments using the Black and Scholes and binomial pricing model. The key assumptions used in the models are the expected future volatility in the price of the Company’s shares, the expected life of the warrants, the risk-free interest rate and the probability of any future adjustment event. Significant Judgments The critical judgments that the Company’s management has made in the process of applying the Company’s accounting policies that have the most significant effect on the amounts recognized in the Company’s consolidated financial statements are as follows: Going Concern The application of the going concern assumption requires management to take into account all available information about the future, which is at least but not limited to, 12 months from the year end of the reporting period. The Company is aware that material uncertainties related to events or conditions raise substantial doubt upon the Company’s ability to continue as a going concern.
Cash and Cash Equivalents	c. Cash and Cash Equivalents The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance, which are readily convertible to known amounts of cash, and which are subject to insignificant risk of changes in value to be cash equivalents.
Provisions	d. Provisions Provisions are recognized where a legal or constructive obligation has been incurred as a result of past events; it is probable that an outflow of resources embodying economic benefit will be required to settle the obligation; and a reliable estimate of the amount of the obligation can be made. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation.
Intangible Assets	e. Intangible Assets Intangible assets consist of patents and patent applications acquired to be used in drug research programs. Intangible assets are carried at cost less accumulated amortization and impairment losses and are capitalized when the costs can be measured reliably, and it is probable that future economic reliably benefits that are attributable to the asset will flow to the Company. The Company amortizes patents over the term of the patent.
Financial Instruments	f. Financial Instruments Financial assets and financial liabilities are recognized when the Company becomes a party to the contractual provisions of the respective instrument. Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities (other than financial assets and financial liabilities at FVTPL) are included in the initial carrying value of the related instrument and are amortized using the effective interest method. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognized immediately in the consolidated statement of operations and comprehensive loss. Financial assets The classification of financial assets depends on the nature and purpose of the financial assets and is determined at the time of initial recognition. Financial assets at FVTPL Financial assets are classified as FVTPL when the financial asset is either held for trading or it is designated as FVTPL. A financial asset is classified as held for trading if: ● it has been acquired principally for the purpose of selling it in the near term; or ● on initial recognition it is part of a portfolio of identified financial instruments that the Company manages together and has a recent actual pattern of short-term profit-taking. Financial assets at amortized cost Financial assets at amortized cost are non-derivative financial assets which are held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. A financial asset (unless it is a trade receivable without a significant financing component that is initially measured at the transaction price) is initially measured at fair value plus, for an item not at FVTPL, transaction costs that are directly attributable to its acquisition. Subsequent to initial recognition, financial assets are measured at amortized cost using the effective interest method, less any impairment. Financial liabilities and equity instruments Classification as debt or equity Debt and equity instruments issued by the Company are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. Equity instruments An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognized as the proceeds received, net of direct issue costs. Other financial liabilities All financial liabilities are measured subsequently at amortized cost using the effective interest method or at FVTPL. Financial liabilities at FVTPL Financial liabilities are classified as at FVTPL when the financial liability is (i) contingent consideration of an acquirer in a business combination, (ii) held for trading or (iii) it is designated as at FVTPL. A financial liability is classified as held for trading if either: ● It has been acquired principally for the purpose of repurchasing it in the near term ● On initial recognition it is part of a portfolio of identified financial instruments that the group manages together and has a recent actual pattern of short-term profit-taking ● It is a derivative, except for a derivative that is a financial guarantee contract or a designated and effective hedging instrument Financial liabilities at FVTPL are measured at fair value, with any gains or losses arising on changes in fair value recognized in profit or loss. Financial liabilities measured subsequently at amortized cost Financial liabilities that are not (i) contingent consideration of an acquirer in a business combination, (ii) held-for-trading, or (iii) designated as at FVTPL, are measured subsequently at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or (where appropriate) a shorter period, to the amortized cost of a financial liability.
Income Taxes	g. Income Taxes Current income tax The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in profit or loss because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The Company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred income tax Deferred income tax is provided using the statement of financial position method on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred income tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that sufficient taxable income will be available to allow all or part of the deferred income tax asset to be utilized. Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred income tax assets and deferred income tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred income taxes relate to the same taxable entity and the same taxation authority.
Foreign Currency Translation	h. Foreign Currency Translation The Company’s reporting currency is the United States dollar. The functional currency for the Company and its subsidiary is the currency of the primary economic environment in which the entity operates. As of November 1, 2023, the functional currency of the Company and its Canadian and Israeli subsidiaries is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated using the exchange rate in effect on the transaction date or at the annual average rate. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange in effect at the consolidated statement of financial position date. Non-monetary items are translated using the historical rate on the date of the transaction. Foreign exchange gains and losses are included in the consolidated statement of operations and comprehensive loss.
Share-based Payments	i. Share-based Payments The grant date fair value of share-based payment awards granted to employees is recognized as stock-based compensation expense, with a corresponding increase in equity, over the period that the employees unconditionally become entitled to the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant date fair value of the share-based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcomes. Where equity instruments are granted to parties other than employees, they are recorded by reference to the fair value of the services received. If the fair value of the services received cannot be reliably estimated, the Company measures the services received by reference to the fair value of the equity instruments granted, measured at the date the counterparty renders service. The fair value of services received from consultants cannot be reliably measured; therefore, the fair value of the underlying equity instruments was utilized for all periods presented. All equity-settled share-based payments are reflected in share-based payment reserve, unless exercised. Upon exercise, shares are issued and the amount reflected in share-based payment reserve is credited to share capital, adjusted for any consideration paid.
Restricted Share Units	j. Restricted Share Units The Company recognizes compensation expense for restricted share units (“RSU’s”) awarded based on the grant-date fair value of the common shares. The grant-date fair value, which is determined by multiplying the Company’s share price by the number of RSU’s granted, is amortized over the vesting period and is included in compensation expense with a corresponding increase in the share-based payment reserve. If RSU’s are for services that have been provided and are non-cancellable, the Company recognizes the full cost of the RSU’s on the date of grant. The amount recognized is adjusted to reflect the number of RSU’s expected to eventually vest.
Leases	k. Leases The Company’s Israeli subsidiary leased an office through to March 31, 2026. At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company reassesses whether a contract is, or contains, a lease only if the terms and conditions of the contract are changed. At the commencement date, the Company measures the lease liability at the present value of the lease payments that are not paid at that date, including, inter alia, the exercise price of a purchase option if the Company is reasonably certain to exercise that option. Simultaneously, the Company recognizes a right-of-use (“ROU”) asset in the amount of the lease liability. The discount rate applied by the Company is the rate of interest that the Company would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the ROU asset in a similar economic environment. The weighted average of lessee’s incremental annual borrowing rate applied to the lease liabilities as of October 31, 2024 was estimated at 10%. The lease term is the non-cancellable period for which the Company has the right to use an underlying asset, together with both, the periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option and periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option. After the commencement date, the Company measures the ROU asset applying the cost model, less any accumulated depreciation and any accumulated impairment losses and adjusted for any remeasurement of the lease liability. Assets are depreciated by the straight-line method over the estimated useful lives of the ROU asset or the lease period, whichever is shorter. Interest on the lease liability is recognized in profit or loss in each period during the lease term in an amount that produces a constant periodic rate of interest on the remaining balance of the lease liability. The Company applied the following practical expedients: ● Non-lease components: practical expedient by class of underlying asset not to separate non-lease components (services) from lease components and, instead, account for each lease component and any associated non lease components as a single lease component. ● The practical expedient for short-term leases is applied.
Research and Development	l. Research and Development Research costs are charged to operations as incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably, the product is technically and commercially feasible, future economic benefits are probable, and the Company intends to or has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized includes the cost of materials, direct labor and overhead costs that are directly attributable to preparing the asset for its intended use and borrowing costs on qualifying assets. Other development expenditures are recognized in the consolidated statement of operations and comprehensive loss as incurred. The Company has not capitalized any development costs for the years ended October 31, 2024, 2023 and 2022.
Loss Per Share	m. Loss Per Share Basic loss per share is computed using the weighted average number of common shares outstanding during the period. The treasury stock method is used for the calculation of diluted loss per share, whereby all “in the money” stock options and share purchase warrants are assumed to have been exercised at the beginning of the period and the proceeds from their exercise are assumed to have been used to purchase common shares at the average market price during the period. When a loss is incurred during the period, basic and diluted loss per share is the same as the exercise of stock options and share purchase warrants is considered to be anti-dilutive. As of October 31, 2024, the Company had 2,819,173 (2023 – 833,810, 2022- 26,419) potentially dilutive shares outstanding.
Deferred offering costs	n. The Company capitalizes certain legal and other third-party fees that are directly related to the Company’s in- process equity financing until such financing is consummated. After consummation of such equity financing, these costs are recorded as a reduction of the respective gross proceeds. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are written off to operating expenses. Where the financing includes both an equity and liability component, pro-rata issuance costs relating to the liability component are charged to the statement of operations.
New and amended IFRS accounting standards that are effective for the current year	o. New and amended IFRS accounting standards that are effective for the current year i) Amendments to IAS 1 Presentation of Financial Statements— The IASB issued a narrow-scope amendment to IAS 1, in January 2020, to clarify that liabilities are classified as either current or non-current, depending on the rights that exist at the end of the reporting period. The amendment could affect the classification of liabilities, particularly for entities that previously considered management’s intentions to determine classification and for some liabilities that can be converted into equity. Inter alia, the amendment requires the following: Liabilities are classified as non-current if the entity has a substantive right to defer settlement for at least 12 months at the end of the reporting period. The amendment no longer refers to unconditional rights. The assessment determines whether a right exists, but it does not consider whether the entity will exercise the right. ’Settlement’ is defined as the extinguishment of a liability with cash, other economic resources or an entity’s own equity instruments. There is an exception for convertible instruments that might be converted into equity, but only for those instruments where the conversion option is classified as an equity instrument as a separate component of a compound financial instrument. The amendments are applied retrospectively for annual periods beginning on or after 1 January 2024, with early application permitted. The amendments had no significant impact on the consolidated financial statements. o. New and amended IFRS accounting standards that are effective for the current year (continued) ii) Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 Making Materiality Judgements - Disclosure of Accounting Policies The amendments change the requirements in IAS 1 with regard to disclosure of accounting policies. The amendments replace all instances of the term ’significant accounting policies’ with ‘material accounting policy information’. Accounting policy information is material if, when considered together with other information included in an entity’s financial statements, it can reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements. The supporting paragraphs in IAS 1 are also amended to clarify that accounting policy information that relates to immaterial transactions, other events or conditions is immaterial and need not be disclosed. Accounting policy information may be material because of the nature of the related transactions, other events or conditions, even if the amounts are immaterial. However, not all accounting policy information relating to material transactions, other events or conditions is itself material. The IASB has also developed guidance and examples to explain and demonstrate the application of the ‘four-step materiality process’ described in IFRS Practice Statement 2. The amendments are applied for annual periods beginning on or after January 1, 2023.
New and revised IFRS Accounting Standards in issue but not yet effective	p. New and revised IFRS Accounting Standards in issue but not yet effective i) IFRS 18 Presentation and Disclosures in Financial Statements IFRS 18 replaces IAS 1, carrying forward many of the requirements in IAS 1 unchanged and complementing them with new requirements. IFRS 18 introduces new requirements to: ● present specified categories and defined subtotals in the statement of profit or loss ● provide disclosures on management-defined performance measures (MPMs) in the notes to the financial statements ● improve aggregation and disaggregation. An entity is required to apply IFRS 18 for annual reporting periods beginning on or after 1 January 2027, with earlier application permitted. The amendments to IAS 7 and IAS 33, as well as the revised IAS 8 and IFRS 7, become effective when an entity applies IFRS 18. IFRS 18 requires retrospective application with specific transition provisions. The Company anticipates that the application of these amendments may have an impact on the consolidated financial statements in future periods.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Oct. 31, 2024
Leases [Abstract]
Schedule of ROU Office Space	ROU Balance, October 31, 2023 $ - Addition 181,779 Early termination of office lease (88,562 ) Accumulated depreciation (39,023 ) Exchange rate differences (2,531 ) Balance, October 31, 2024 $ 51,663
Schedule of Lease Liability	Lease Balance, October 31, 2023 $ - Addition 181,779 Early termination of office lease (88,905 ) Lease payments (42,587 ) Interest expense 5,386 Exchange rate differences (2,531 ) Balance, October 31, 2024 $ 53,142
Schedule of Amounts Recognized in Profit or Loss	Year ended October 31, 2024 Depreciation $ 39,023 Interest 5,386 $ 44,409

Short-Term Investments (Tables)

Short-Term Investments (Tables)	12 Months Ended
	Oct. 31, 2024
Short-term Investments [Abstract]
Schedule of Fair Value of Common Shares	October 31, Additions Disposals Changes in October 31, Polyrizon Ltd. – shares and warrants (1) $ - $ 350,400 $ - $ (61,012 ) $ 289,388 Xylo Technologies Ltd. – shares (2) 86,112 - (78,500 ) (7,612 ) - $ 86,112 $ 350,400 $ (78,500 ) $ (68,624 ) $ 289,388 October 31, Additions Disposals Changes in fair value October 31, Xylo Technologies Ltd. – shares (2) $ 193,750 $ - $ - $ (107,638 ) $ 86,112 (1) On October 30, 2024, the Company subscribed for 80,000 shares and 240,000 warrants (“Polyrizon Warrants”) of Polyrizon Ltd. (“Polyrizon”) in Polyrizon’s initial public offering on the Nasdaq at a cost of $350,400. Each Polyrizon Warrant can be exercised into one ordinary share of Polyrizon at an exercise price of $4.38 per share. The Polyrizon Warrants expire on October 29, 2029. The fair value of the Polyrizon Warrants as of October 31, 2024, was $178,988 based on the Block-Scholes option pricing model, using the following assumptions: risk-free rate of 4.28%, expected life of 5 years and volatility of 92%. See note 19a. (2) Pursuant to the Share Exchange Agreement with Xylo Technologies Ltd. (formerly known as Medigus Ltd.) (“Xylo”), on February 14, 2022, the Company received 27,778 ordinary shares of Xylo. The investment cost of the share was $501,938.

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Oct. 31, 2024
Related Party Transactions [Abstract]
Schedule of Key Management Personnel for Employment Services	The compensation to key management personnel for employment services they provide to the Company is as follows: Year ended Year ended Year ended October 31, October 31, October 31, 2024 2023 2022 Officers: Payroll and other short-term benefits $ - $ - $ 32,533 Consulting fees 422,522 410,066 453,519 Share based compensation 185,843 124,808 772,786 $ 608,365 $ 534,874 $ 1,258,838 Directors: Directors’ fees and payroll $ 242,603 $ 182,261 $ 124,746 Share based compensation 296,728 121,981 43,485 $ 539,331 $ 304,242 $ 168,231
Schedule of Balances with Related Parties	Balances with related parties October 31, October 31, 2024 2023 Amounts owed to officers $ 29,498 $ 29,666 Amounts owed to directors 19,464 12,767 $ 48,962 $ 42,433

Derivative Warrant Liabilities

Derivative Warrant Liabilities (Tables)	12 Months Ended
	Oct. 31, 2024
Derivative Warrant Liabilities [Abstract]
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability	The binomial model was used to measure the derivative warrant liability with the following assumptions: October 31, Share Price $ 1.39 Exercise Price $ 1.077-$1.60 Expected life 3.43-4.21 years Risk-free interest rate 4.13-4.14 % Dividend yield 0.00 % Expected volatility 143.59-147.59 %
Schedule of Changes in the Warrant Liability	The following table presents the changes in the warrant liability during the period: Balance as of November 1, 2022 $ - Issuance of April 2023 Warrants 1,771,208 Issuance of September 2023 Warrants 923,225 Exercise of warrants (574,040 ) Changes in fair value of warrants 2,189,986 Balance as of October 31, 2023 $ 4,310,379 Issuance of January 2024 Warrants 480,004 Exercise of warrants (562,879) Changes in fair value of warrants (707,802) Balance as of October 31, 2024 $ 3,519,702

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Oct. 31, 2024
Share Capital [Abstract]
Schedule of Fair Value of Underwriters Warrants	The fair value of the underwriters warrants was estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Risk-free interest rate 1.43 % Expected life (in years) 5 Expected volatility 150 %

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Oct. 31, 2024
Warrants [Abstract]
Schedule of Changes in Warrants	The following table summarizes the changes in the Company’s warrants: Number of Historic weighted Balance, October 31, 2022 19,763 576.66 Issuance of underwriter warrants 1,923 243.75 Issuance of April 2023 warrants (*) 4,505,718 5.124 Issuance of September 2023 warrants (*) 7,500,000 9.00 Issuance of Xylo warrants 75 1,297.67 Expiration of warrants (11,430 ) 922.98 Exercise of warrants (784,584 ) 5.124 Balance, October 31, 2023 11,231,465 $ 7.90 Number of shares to be issued from the exercise of these warrants, October 31, 2023 826,781 Balance, October 31, 2023 11,231,465 $ 7.90 Issuance of January 2024 warrants (Note 7c) (*) 1,500,000 1.60 Exercise of warrants (8,293,585 ) 2.62 Expiration of warrants (8,333 ) 98.43 Balance, October 31, 2024 (**) 4,429,547 $ 1.57 Number of shares to be issued from the exercise of these warrants 2,549,311 (*) These warrants include a cashless exercise provision and repricing provisions under certain circumstances, that also includes a potential change in the number of shares to be issued for each warrant depending on the change in the exercise price of the warrant. See table below for number of shares to be issued from the exercise of warrants. (**) See note 19(b) regarding the exercise of warrants.
Schedule of Share Purchase Warrants were Outstanding	As of October 31, 2024, the following share purchase warrants were outstanding: Number of Number of shares Exercise price per Exercise price per Expiry date 1,923 1,923 C$ 339.20 $ 243.75 November 17, 2027 743,565 538,150 $ 1.077 $ 1.077 April 5, 2028 75 75 C$ 1,800 $ 1,293.48 November 23, 2024 2,352,504 677,683 $ 1.077 $ 1.077 September 17, 2028 1,331,480 1,331,480 $ 1.60 $ 1.60 January 15, 2029 4,429,547 2,549,311

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Oct. 31, 2024
Stock Options [Abstract]
Schedule of Changes in Stock Options	The following table summarizes the changes in the Company’s stock options for the years ended October 31, 2024 and October 31, 2023: Number of Weighted Weighted Outstanding, October 31, 2022 5,254 C$ 613.5 $ 450.64 Granted (i, ii, iii) 334 442.22 318.81 Outstanding, October 31, 2023 5,588 C$ 603.12 $ 434.82 Expired (67 ) 720.00 533.14 Outstanding, October 31, 2024 5,521 C$ 601.71 $ 432.38 Exercisable, October 31, 2024 5,351 C$ 603.50 $ 433.67 i) On May 23, 2023, the Company granted 61 stock options to a consultant of the Company. The options are exercisable at $227.09 (CAD$315.00) per share. The options expire on May 23, 2033. ii) On June 26, 2023, the Company granted 223 stock options to a consultant of the Company. The 156 options are exercisable at $363.35 (CAD$504.00) per share and the 67 options are exercisable at $519.07 (CAD$720.00) per share. The options expire on June 26, 2033. iii) On July 6, 2023, the Company granted 50 stock options to a consultant of the Company. The options are exercisable at $23.40 per share. The options expire on July 6, 2033.
Schedule of Additional Information Regarding Stock Options Outstanding	Additional information regarding stock options outstanding as of October 31, 2024, is as follows: Outstanding Exercisable Number of Weighted Weighted Weighted Number of Weighted Weighted 533 1.57 C$ 166.50 $ 119.65 533 C$ 166.50 $ 119.65 978 7.26 504.00 362.17 920 504.00 362.17 1,166 1.56 675.00 485.05 1,166 675.00 485.05 200 4.49 702.00 504.46 200 702.00 504.46 133 1.88 747.00 536.79 133 747.00 536.79 422 7.11 612.00 439.78 422 612.00 439.78 1,044 7.26 720.00 517.39 957 720.00 517.39 667 1.67 756.00 543.26 667 756.00 543.26 111 7.11 900.00 646.74 111 900.00 646.74 61 8.56 315.00 226.36 61 315.00 226.36 156 8.66 504.00 362.17 156 504.00 362.17 50 8.68 32.56 23.40 25 32.56 23.40 5,521 4.65 C$ 601.71 $ 432.38 5,351 C$ 603.50 $ 433.67
Schedule of Fair Value of Stock Options	The fair value of stock options previously granted to certain consultants for ongoing services measured during the period have been estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Year ended October 31, 2024 2023 Risk-free interest rate 4.22 % 4.10 % Expected life (in years) 4.61 5.61 Expected volatility 125.77-133.62 % 140.41-160.81 %

Restricted Share Units (Tables)

Restricted Share Units (Tables)	12 Months Ended
	Oct. 31, 2024
Restricted Share Units [Abstract]
Schedule of Changes in RSUs	The following table summarizes the changes in RSUs: Number of Weighted Weighted Balance, October 31, 2022 1,407 $ 375.54 $ 273.42 Granted 2,200 55.97 41.63 Exercised (1,391 ) 246.64 189.37 Balance, October 31, 2023 2,216 $ 138.55 $ 96.06 Granted (i) 591,460 1.86 1.36 Exercised (329,338 ) 2.22 1.65 Balance, October 31, 2024 264,338 $ 2.55 $ 1.80 (i) During the year ended October 31, 2024, the Company issued 591,460 RSU’s to consultants, directors and officers. The RSU’s vested with a fair value of $804,962 (2023-$91,589).

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	12 Months Ended
	Oct. 31, 2024
Financial Instruments and Risk Management [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value	Assets and liabilities measured at fair value on a recurring basis were presented on the Company’s statement of financial position as of October 31, 2024, as follows: Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment- shares $ 110,400 $ – $ – $ 110,400 Short-term investment- Polyrizon Warrants – – 178,988 178,988 Derivative warrant liabilities – – 3,519,702 3,519,702 Assets and liabilities measured at fair value on a recurring basis were presented on the Company’s statement of financial position as of October 31, 2023, as follows: Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment $ 86,112 $ – $ – $ 86,112 Derivative warrant liabilities – – 4,310,379 4,310,379
Schedule of Foreign Currency Exchange Risk on Net Working Capital	The following table indicates the impact of foreign currency exchange risk on net working capital as of October 31, 2024. The table below also provides a sensitivity analysis of a 10% strengthening of the foreign currency against functional currencies identified which would have increased (decreased) the Company’s net loss by the amounts shown in the table below. A 10% weakening of the foreign currency against the functional currencies would have had the equal but opposite effect as of October 31, 2024. Cash and cash equivalents $ 137,666 Amounts receivable 49,038 Accounts payable and accrued liabilities (192,971 ) Due to related parties (38,962 ) Total foreign currency financial assets and liabilities $ (45,229 ) Impact of a 10% strengthening or weakening of foreign exchange rate $ (4,523 )
Schedule of Contractual Maturities of Financial Liabilities	The following amounts are the contractual maturities of financial liabilities as of October 31, 2024 and 2023: October 31, 2024 Total Within Within Accounts payable and accrued liabilities $ 526,056 $ 526,056 $ – Due to related parties 48,962 48,962 – Lease liability 53,142 36,726 16,416 $ 628,160 $ 611,744 $ 16,416 October 31, 2023 Total Within Within Accounts payable and accrued liabilities $ 617,004 $ 617,004 $ – Due to related parties 42,433 42,433 – $ 659,437 $ 659,437 $ –

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Oct. 31, 2024
Income Taxes [Abstract]
Schedule of Deferred Income Tax Assets and Liabilities	The tax effect (computed by applying the Canadian federal and provincial statutory rate) of the significant differences, which comprise deferred income tax assets and liabilities, are as follows: 2024 2023 2022 Canadian statutory income tax rate 27 % 27 % 27 % Income tax recovery at statutory rate (1,316,712 ) (2,322,936 ) (1,861,476 ) Tax effect of: Items not deductible for tax purposes (20,556 ) 223,809 335,494 Over provided in prior years (384,109 ) (19,674 ) - Tax rate difference for foreign jurisdiction (5,365 ) 10,715 56,175 Change in unrecognized deferred income tax assets 2,104,708 2,125,459 1,499,666 Income tax provision 377,966 17,372 29,859
Schedule of Canadian Non-Capital Losses Carried Forward	As of October 31, 2024, the Company has Canadian non-capital losses carried forward of $20,281,000, which is available to offset future years’ taxable income in Canada. These losses expire as follows: $ 2037 5,000 2038 73,000 2039 71,000 2040 169,000 2041 1,142,000 2042 4,716,000 2043 8,678,000 2044 5,427,000 20,281,000

General and Administrative Ex_2

General and Administrative Expenses (Tables)	12 Months Ended
	Oct. 31, 2024
General and Administrative Expenses [Abstract]
Schedule of General and Administrative Expenses	Year ended Year ended Year ended October 31, October 31, October 31, 2024 2023 2022 Professional fees $ 1,998,625 $ 2,210,795 $ 1,093,871 Investor relations 440,041 1,565,970 473,106 Share-based compensation (Notes 6, 10 and 11) 1,119,041 243,717 946,324 Consulting fees (Note 6) 131,769 96,421 192,448 Insurance 329,278 364,059 149,537 Transfer agent and regulatory fees 190,397 171,439 86,605 Depreciation of ROU asset 39,023 35,381 60,665 Salaries and benefits (Note 6) 57,340 37,838 92,296 Office and miscellaneous 55,538 31,670 68,016 Depreciation of property and equipment 1,065 1,915 7,572 Total general and administrative $ 4,362,117 $ 4,759,205 $ 3,170,440

Research and Development, Net (

Research and Development, Net (Tables)	12 Months Ended
	Oct. 31, 2024
Research and Development, Net [Abstract]
Schedule of Research and Development, Net	Year ended Year ended Year ended October 31, October 31, October 31, 2024 2023 2022 Research and preclinical studies $ 747,026 $ 1,159,147 $ 2,380,942 Salaries, regulatory, professional and other expenses 542,615 469,667 666,125 Share-based compensation (Notes 6, 10 and 11) 132,502 45,870 213,299 Reimbursements (Note 6) (50,319 ) (141,409 ) (194,205 ) Amortization of intangible assets 10,984 10,954 14,830 Total research and development, net $ 1,382,808 $ 1,544,229 $ 3,080,991

Nature of Operations and Goin_2

Nature of Operations and Going Concern (Details) - USD ($)						1 Months Ended	12 Months Ended
	Oct. 30, 2024	Nov. 28, 2023	Sep. 18, 2023	Apr. 06, 2023	Sep. 30, 2022	Jan. 16, 2024	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2022
Nature of Operations and Going Concern [Line Items]
Cash flow from operations							$ (4,858,659)	$ (6,301,472)	$ (3,724,494)
Accumulated deficit							$ (24,022,741)	$ (18,768,063)
Common shares (in Shares)		1			1
Description of currency exchange rate							The change in the functional currency was accounted for prospectively from the date of the change by translating all items of the financial statement into the new functional currency using the exchange rate of $0.7327 CAD/USD at the date of the change.
public offering [Member]
Nature of Operations and Going Concern [Line Items]
Gross proceeds	$ 350,400		$ 2,250,000	$ 3,500,000
Net proceeds			$ 1,800,000	$ 2,900,000
Private Placement [Member]
Nature of Operations and Going Concern [Line Items]
Gross proceeds						$ 2,400,000
Ordinary shares [member]
Nature of Operations and Going Concern [Line Items]
Common shares received per share (in Dollars per share)		$ 0.0333			$ 0.0333

Material Accounting Policies (D

Material Accounting Policies (Details) - shares	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2022
Material Accounting Policies [Abstract]
Maturity period	3 months
Lease liabilities percentage	10%
Dilutive shares outstanding	2,819,173	833,810	26,419

Intangible Assets (Details)

Intangible Assets (Details)	May 04, 2021 USD ($)
Intellectual Property [Member]
Intangible Assets [Line Items]
Paid to acquire intellectual property	$ 160,000
Patents [Member]
Intangible Assets [Line Items]
Estimated remaining life	14 years 7 months 6 days

Leases (Details)

Leases (Details)						12 Months Ended
	Jun. 13, 2024 USD ($) m²	Jun. 13, 2024 ILS (₪) m²	Mar. 31, 2024 USD ($)	Dec. 25, 2023 USD ($) m²	Dec. 25, 2023 ILS (₪) m²	Oct. 31, 2024 USD ($) m²	Oct. 31, 2024 ILS (₪) m²
Leases [Line Items]
Total area of land	193	193		120	120
Estimated incremental borrowing percentage	10%	10%		10%	10%
Rent increased	$ 3,400	₪ 12,500		$ 6,500	₪ 23,300
Termination fees | $			$ 13,000
Payment for termination fees | $			$ 3,000
Tel Aviv [Member]
Leases [Line Items]
Total area of land	386	386		240	240
2021 Lease [Member]
Leases [Line Items]
Total area of land						120	120
Extend lease description						The Company, Scisparc and the third party had an option to extend the 2021 Lease for an additional three-year period. The Company’s base rent was ILS11,000 per month (approximately $3,080) during the term of the 2021 Lease.	The Company, Scisparc and the third party had an option to extend the 2021 Lease for an additional three-year period. The Company’s base rent was ILS11,000 per month (approximately $3,080) during the term of the 2021 Lease.
Estimated incremental borrowing percentage						20%	20%
Rent increased						$ (5,094)	₪ 18,200

Leases - Schedule of ROU Office

Leases - Schedule of ROU Office Space (Details) - Office space lease [Member	12 Months Ended
	Oct. 31, 2024 USD ($)
Leases - Schedule of ROU Office Space (Details) [Line Items]
Balance at beginning
Addition	181,779
Early termination of office lease	(88,562)
Accumulated depreciation	(39,023)
Exchange rate differences	(2,531)
Balance at ending	$ 51,663

Leases - Schedule of Lease Liab

Leases - Schedule of Lease Liability (Details) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2022
Schedule of Lease Liability [Abstract]
Balance at beginning
Addition	181,779
Early termination of office lease	(88,905)
Lease payments	(42,587)	$ (40,922)	$ (70,870)
Interest expense	5,386	2,907	$ 14,433
Exchange rate differences	(2,531)
Balance at ending	$ 53,142

Leases - Schedule of Amounts Re

Leases - Schedule of Amounts Recognized in Profit or Loss (Details)	12 Months Ended
	Oct. 31, 2024 USD ($)
Schedule Of Amounts Recognized In Profit Or Loss [Abstract]
Depreciation	$ 39,023
Interest	5,386
Total amounts recognized in profit or loss	$ 44,409

Short-Term Investments (Details

Short-Term Investments (Details) - USD ($)					12 Months Ended
	Oct. 31, 2024	Oct. 30, 2024	Sep. 18, 2023	Apr. 06, 2023	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2022	Feb. 14, 2022
Short-term Investments [Line Items]
Shares issued (in Shares)		80,000						2,208
Warrants exercised (in Shares)		1
Exercise price (in Dollars per share)		$ 4.38
Fair value warrants					$ 4,104,521	$ 590,077
Risk-free rate percentage	4.28%
Volatility percentage	92%
Investment cost					501,938
Total proceeds					78,500
Changes in fair value amount					$ 7,612
Excepted life	5
Medigus Ltd [Member]
Short-term Investments [Line Items]
Ordinary shares received (in Shares)								27,778
Polyrizon warrants [Member]
Short-term Investments [Line Items]
Shares issued (in Shares)		240,000
Fair value warrants	$ 178,988
public offering [Member]
Short-term Investments [Line Items]
Public offering		$ 350,400	$ 2,250,000	$ 3,500,000

Short-Term Investments - Schedu

Short-Term Investments - Schedule of Fair Value of Common Shares (Details) - USD ($)		12 Months Ended
		Oct. 31, 2024	Oct. 31, 2023
Polyrizon Ltd [Member]
Schedule of Fair Value of Common Shares [Line Items]
Beginning shares	[1]
Additions	[1]	350,400
Disposals	[1]
Changes in fair value	[1]	(61,012)
Ending shares	[1]	289,388
Xylo Technologies Ltd [Member]
Schedule of Fair Value of Common Shares [Line Items]
Beginning shares	[2]	86,112
Additions	[2]
Disposals	[2]	(78,500)
Changes in fair value	[2]	(7,612)
Ending shares	[2]		86,112
Short-term Investment [Member]
Schedule of Fair Value of Common Shares [Line Items]
Beginning shares		86,112
Additions		350,400
Disposals		(78,500)
Changes in fair value		(68,624)
Ending shares		289,388	86,112
Xylo Technologies Ltd. – shares [Member]
Schedule of Fair Value of Common Shares [Line Items]
Beginning shares	[2]	$ 86,112	193,750
Additions	[2]
Disposals	[2]
Changes in fair value	[2]		(107,638)
Ending shares	[2]		$ 86,112
[1] On October 30, 2024, the Company subscribed for 80,000 shares and 240,000 warrants (“Polyrizon Warrants”) of Polyrizon Ltd. (“Polyrizon”) in Polyrizon’s initial public offering on the Nasdaq at a cost of $350,400. Each Polyrizon Warrant can be exercised into one ordinary share of Polyrizon at an exercise price of $4.38 per share. The Polyrizon Warrants expire on October 29, 2029. The fair value of the Polyrizon Warrants as of October 31, 2024, was $178,988 based on the Block-Scholes option pricing model, using the following assumptions: risk-free rate of 4.28%, expected life of 5 years and volatility of 92%. See note 19a. Pursuant to the Share Exchange Agreement with Xylo Technologies Ltd. (formerly known as Medigus Ltd.) (“Xylo”), on February 14, 2022, the Company received 27,778 ordinary shares of Xylo. The investment cost of the share was $501,938.

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2022
Disclosure of transactions between related parties [line items]
Incurred research and development expenses	$ 1,382,808	$ 1,544,229	$ 3,080,991
Owed to the Company	$ 131,839	136,002
SciSparc Ltd [Member]
Disclosure of transactions between related parties [line items]
Percentage of economics and rights held in joint venture	50%
Incurred research and development expenses	$ 50,319	$ 141,409	$ 194,205

Related Party Transactions - Sc

Related Party Transactions - Schedule of Key Management Personnel for Employment Services (Details) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2022
Officers [Member]
Officers:
Payroll and other short-term benefits			$ 32,533
Consulting fees	422,522	410,066	453,519
Share based compensation	185,843	124,808	772,786
key management personnel compensation	608,365	534,874	1,258,838
Directors [Member]
Officers:
Directors’ fees and payroll	242,603	182,261	124,746
Share based compensation	296,728	121,981	43,485
key management personnel compensation	$ 539,331	$ 304,242	$ 168,231

Related Party Transactions - _2

Related Party Transactions - Schedule of Balances with Related Parties (Details) - USD ($)	Oct. 31, 2024	Oct. 31, 2023
Disclosure of transactions between related parties [line items]
Balances with related parties	$ 48,962	$ 42,433
Amounts owed to officers [Member]
Disclosure of transactions between related parties [line items]
Balances with related parties	29,498	29,666
Amounts owed to directors [Member]
Disclosure of transactions between related parties [line items]
Balances with related parties	$ 19,464	$ 12,767

Derivative Warrant Liabilitie_2

Derivative Warrant Liabilities (Details)							1 Months Ended		12 Months Ended
	Aug. 12, 2024 shares	Jun. 28, 2024 shares	Mar. 22, 2024 shares	Feb. 23, 2024 shares	Jan. 21, 2024 $ / shares	Dec. 05, 2023 shares	Jul. 16, 2024 shares	Mar. 22, 2024 shares	Oct. 31, 2024 USD ($)	Jan. 16, 2024 $ / shares shares	Sep. 18, 2023 shares	Apr. 06, 2023 shares
April 2023 Warrants [Member]
Derivative Warrant Liabilities [Line Items]
Number of shares issued	64,104	156,098	27,973			2,729,394		27,973				4,505,718
Exercise price (in Dollars per share) | $ / shares					$ 1.077
Convertible common shares (in Dollars per share) | $ / shares					0.724
Warrants exercised common share	46,395	112,975	20,245			652,521
September 2023 Warrants [Member]
Derivative Warrant Liabilities [Line Items]
Number of shares issued	80,526	182,144	281,910			4,602,916		281,910			7,500,000
Exercise price (in Dollars per share) | $ / shares					1.077
Convertible common shares (in Dollars per share) | $ / shares					$ 0.288
Warrants exercised common share	23,197	54,877				409,667		81,469
January 2024 Warrants [Member]
Derivative Warrant Liabilities [Line Items]
Number of shares issued				30,200			138,320			1,500,000
Exercise price (in Dollars per share) | $ / shares										$ 1.6
Warrants exercised common share				30,200			138,320
Warrants [member]
Derivative Warrant Liabilities [Line Items]
Changes in fair value of derivative warrant liabilities (in Dollars) | $									$ 707,802
Expected life									4.21

Derivative Warrant Liabilitie_3

Derivative Warrant Liabilities - Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability (Details)	Oct. 31, 2024
Share price [Member]
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Derivative warrant liability measurement inputs	1.39
Exercise price [Member] | Bottom of range [member]
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Derivative warrant liability measurement inputs	1.077
Exercise price [Member] | Top of range [member]
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Derivative warrant liability measurement inputs	1.6
Expected life [Member] | Bottom of range [member]
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Derivative warrant liability measurement inputs	3.43
Expected life [Member] | Top of range [member]
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Derivative warrant liability measurement inputs	4.21
Risk-free interest rate [Member] | Bottom of range [member]
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Derivative warrant liability measurement inputs	4.13
Risk-free interest rate [Member] | Top of range [member]
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Derivative warrant liability measurement inputs	4.14
Dividend yield [Member]
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Derivative warrant liability measurement inputs	0
Expected volatility [Member] | Bottom of range [member]
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Derivative warrant liability measurement inputs	143.59
Expected volatility [Member] | Top of range [member]
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Derivative warrant liability measurement inputs	147.59

Derivative Warrant Liabilitie_4

Derivative Warrant Liabilities - Schedule of Changes in the Warrant Liability (Details) - Warrants [member] - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Schedule of Changes in the Warrant Liability [Line Items]
Balance at beginning	$ 4,310,379
Exercise of warrants		(574,040)
Changes in fair value of warrants		2,189,986
Balance at ending		4,310,379
April 2023 Warrants [Member]
Schedule of Changes in the Warrant Liability [Line Items]
Issuance of Warrants		1,771,208
September 2023 Warrants [Member]
Schedule of Changes in the Warrant Liability [Line Items]
Issuance of Warrants		$ 923,225
January 2024 Warrants [Member]
Schedule of Changes in the Warrant Liability [Line Items]
Issuance of Warrants	480,004
Exercise of warrants	(562,879)
Changes in fair value of warrants	(707,802)
Balance at ending	$ 3,519,702

Share Capital (Details)

Share Capital (Details)																											1 Months Ended			12 Months Ended
	Oct. 31, 2024 USD ($) $ / shares shares	Aug. 12, 2024 USD ($) shares	Jul. 08, 2024 USD ($) shares	Jul. 04, 2024 USD ($) shares	Jun. 17, 2024 USD ($) shares	May 09, 2024 USD ($) shares	Apr. 03, 2024 USD ($) shares	Feb. 19, 2024 USD ($) shares	Jan. 16, 2024 USD ($) $ / shares shares	Dec. 11, 2023 USD ($) shares	Nov. 06, 2023 USD ($) shares	Oct. 20, 2023 USD ($) shares	Sep. 18, 2023 USD ($) $ / shares shares	Aug. 28, 2023 USD ($) shares	Aug. 18, 2023 USD ($)	Jun. 10, 2023 USD ($) shares	Jun. 01, 2023 USD ($) shares	May 23, 2023 USD ($) shares	Apr. 06, 2023 USD ($) $ / shares shares	Feb. 22, 2023 USD ($) shares	Jan. 16, 2023 USD ($) shares	Nov. 17, 2022 USD ($)	Nov. 14, 2022 USD ($) $ / shares shares	Feb. 14, 2022 USD ($) shares	Feb. 14, 2022 $ / shares shares	Nov. 26, 2021 USD ($) shares	Sep. 19, 2024 USD ($) shares	Jul. 16, 2024 USD ($) shares	Mar. 26, 2024 USD ($)	Oct. 31, 2024 USD ($) $ / shares shares	Oct. 31, 2023 USD ($) shares	Oct. 31, 2022 USD ($) shares	Oct. 30, 2024 $ / shares shares	Jun. 29, 2024 shares	Jun. 28, 2024 shares	Mar. 22, 2024 shares	Jan. 21, 2024 $ / shares	Dec. 05, 2023 shares
Share Capital [Line Items]
Number of shares issued																								2,208	2,208								80,000
Common shares fair value (in Dollars) | $						$ 127		$ 68			$ 117							$ 27,965												$ 455,487
Gross proceeds from warrants exercised (in Dollars) | $																														$ 4,104,521	$ 590,077
Direct offering and private pacement common shares									1,468,000
Warrants purchase													24,167						46,942
Unregistered common warrants									1,500,000
Exercise price (in Dollars per share) | $ / shares																																	$ 4.38
Expire term									5 years
Gross proceeds from offering (in Dollars) | $									$ 2,400,000
Net proceeds from offering (in Dollars) | $									$ 1,824,773						$ 1,814,193				$ 2,936,079
Fair value of RSU (in Dollars) | $			$ 256,252		$ 243,003		$ 11,935							$ 65,143		$ 10,000	$ 48,194			$ 110,096	$ 39,975						$ 30,645
Issuance of common share																							38,462
Purchase price per share (in Dollars per share) | $ / shares	$ 195																													$ 195
Aggregate gross proceeds (in Dollars) | $																							$ 7,500,000
Underwriters option period																														45 days
Additional common shares																														5,769
Common shares percentage																														15%
Underwriter warrants																														1,923
Fair value of underwriter warrants (in Dollars) | $	$ 337,579																													$ 337,579
Underwritten public offering													225,833						103,249
Price per share | (per share)																			$ 23.4						$ 60
Pre-funded warrants per share (in Dollars per share) | $ / shares													$ 8.97						23.37
Pre-Funded warrants exercisable (in Dollars per share) | $ / shares													0.03						0.03
Exercise price per common share (in Dollars per share) | $ / shares																			$ 23.4
Consideration amount (in Dollars) | $																								$ 750,000
Warrant exercisable, term																								18 months
Units issued																														883
Price per unit (in Dollars per share) | $ / shares	$ 720																													$ 720
Gross proceeds (in Dollars) | $																														$ 698,897
Finder’s fees (in Dollars) | $																														69,890
Risk-free rate	4.28%
Expected life	5
Volatility	92%
Changes in fair value of derivative warrant liabilities (in Dollars) | $																														$ 707,802	$ (2,189,986)	$ (290,569)
Common Shares [Member]
Share Capital [Line Items]
Number of shares outstanding	4,265,186																													4,265,186	607,337
Number of shares issued	4,265,186		134,868	64,617		88		44			45			585		597	245	239		400	161					44	22,500			4,265,186	607,337
Common shares fair value (in Dollars) | $	$ 269,453			$ 98,218																										$ 372,745
Net proceeds from offering (in Dollars) | $																						$ 6,363,906
Purchase price per share (in Dollars per share) | $ / shares																							$ 195
Payment per share (in Dollars per share) | $ / shares																														$ 243.75
Price per share | $ / shares													$ 9
Units issued																														1,325
Investors [Member]
Share Capital [Line Items]
Number of shares issued														44				1,494
Common shares fair value (in Dollars) | $														$ 607				$ 110,000
Investors [Member] | Common Shares [Member]
Share Capital [Line Items]
Number of shares issued																											193,851
Xylo SPA [Member]
Share Capital [Line Items]
Number of shares issued																		1,494						27,778	27,778									1,494
Shareholder equity (in Dollars) | $	$ 296,845																													$ 296,845
Finder’s fees (in Dollars) | $																														$ 50,000
Chief Science Office [Member]
Share Capital [Line Items]
Common shares fair value (in Dollars) | $																								$ 17,584		$ 21,100
Chief Science Office [Member] | Common Shares [Member]
Share Capital [Line Items]
Number of shares issued																								45	45
RSU’s [Member]
Share Capital [Line Items]
Number of shares issued	264,338																													264,338	2,216	1,407
RSU’s [Member] | Common Shares [Member]
Share Capital [Line Items]
Number of shares issued					162,970		9,000
April 2023 Warrants and September 2023 Warrants [Member]
Share Capital [Line Items]
Warrants exercised into common shares		69,592								1,062,188
Gross proceeds from warrants exercised (in Dollars) | $		$ 74,999								$ 3,498,032
Pre-Funded Warrants [Member]
Share Capital [Line Items]
Warrants purchase									32,000
Exercise price (in Dollars per share) | $ / shares									$ 0.0001
Expire term																			5 years
Aggregate gross proceeds (in Dollars) | $													$ 2,250,000						$ 3,500,000
Pre-Funded Warrants [Member] | Common Shares [Member]
Share Capital [Line Items]
Common shares									32,000
Unregistered Common Warrants [Member]
Share Capital [Line Items]
Common shares									1,500,000
Exercise price (in Dollars per share) | $ / shares									$ 1.6
April 2023 Warrants September 2023 Warrants and January 2024 Warrants [Member]
Share Capital [Line Items]
Warrants exercised into common shares																												306,172
Gross proceeds from warrants exercised (in Dollars) | $																												$ 402,206	$ 157,918
Exercised shares																													131,914
September 2023 Public Offering Warrant [Member]
Share Capital [Line Items]
Expire term													5 years
Exercise price per common share (in Dollars per share) | $ / shares													$ 9
April 2023 Warrants [Member]
Share Capital [Line Items]
Number of shares issued		64,104																	4,505,718																156,098	27,973		2,729,394
Common shares fair value (in Dollars) | $												$ 574,040
Warrants exercised into common shares												119,433
Exercise price (in Dollars per share) | $ / shares																																					$ 1.077
Number of warrant shares												784,584
Warrants [member]
Share Capital [Line Items]
Common shares fair value (in Dollars) | $																														$ 82,742
Risk-free rate																														1.43%
Expected life																														1.5
Volatility																														107.46%
Warrants [member] | Xylo SPA [Member]
Share Capital [Line Items]
Number of shares issued																		75																75

Share Capital - Schedule of Fai

Share Capital - Schedule of Fair Value of Underwriters Warrants (Details) - Option Pricing Model [Member]	12 Months Ended
	Oct. 31, 2024
Schedule of Fair Value of Underwriters Warrants [Line Items]
Risk-free interest rate	1.43%
Expected life (in years)	5
Expected volatility	150%

Warrants - Schedule of Changes

Warrants - Schedule of Changes in Warrants (Details)		12 Months Ended
		Oct. 31, 2024 $ / shares shares		Oct. 31, 2023 $ / shares shares
Schedule of Changes in Warrants [Abstract]
Number of warrants, Balance beginning		11,231,465		19,763
Historic weighted average price, Balance beginning		$ 7.9		$ 576.66
Number of warrants, Issuance of underwriter warrants (in Shares) | shares				1,923
Historic weighted average exercise price, Issuance of underwriter warrants				$ 243.75
Number of warrants, Issuance of warrants (in Shares) | shares	[1]	1,500,000		4,505,718
Historic weighted average exercise price, Issuance of warrants	[1]	$ 1.6		$ 5.124
Number of warrants, Issuance of warrants (in Shares) | shares	[1]			7,500,000
Historic weighted average exercise price, Issuance of warrants	[1]			$ 9
Number of warrants, Issuance of XYLO warrants (in Shares) | shares				75
Historic weighted average exercise price, Issuance of XYLO warrants				$ 1,297.67
Number of warrants, Expiration of warrants		(8,333)		(11,430)
Historic weighted average exercise price, Expiration of warrants		$ 98.43		$ 922.98
Number of warrants, Exercise of warrants		(8,293,585)		(784,584)
Historic weighted average exercise price, Exercise of warrants		$ 2.62		$ 5.124
Number of warrants, Balance ending		4,429,547	[2]	11,231,465
Historic weighted average price, Balance ending		$ 1.57	[2]	$ 7.9
Number of warrants, Number of shares to be issued from the exercise of warrants (in Shares) | shares		2,549,311		826,781
[1]These warrants include a cashless exercise provision and repricing provisions under certain circumstances, that also includes a potential change in the number of shares to be issued for each warrant depending on the change in the exercise price of the warrant. See table below for number of shares to be issued from the exercise of warrants.[2]See note 19(b) regarding the exercise of warrants.

Warrants - Schedule of Share Pu

Warrants - Schedule of Share Purchase Warrants were Outstanding (Details)	12 Months Ended
	Oct. 31, 2024 $ / shares shares	Oct. 31, 2024 $ / shares shares	Oct. 30, 2024 $ / shares
Schedule of Share Purchase Warrants were Outstanding [Line Items]
Number of warrants outstanding	4,429,547	4,429,547
Number of shares to be issued from the exercise of warrants (warrant shares)	2,549,311	2,549,311
Exercise price per warrant shares (in Dollars per share and Dollars per share) | $ / shares			$ 4.38
November 17, 2027 [Member]
Schedule of Share Purchase Warrants were Outstanding [Line Items]
Number of warrants outstanding	1,923	1,923
Number of shares to be issued from the exercise of warrants (warrant shares)	1,923	1,923
Exercise price per warrant shares (in Dollars per share and Dollars per share) | (per share)	$ 243.75	$ 339.2
Expiry date	Nov. 17, 2027
April 5, 2028 [Member]
Schedule of Share Purchase Warrants were Outstanding [Line Items]
Number of warrants outstanding	743,565	743,565
Number of shares to be issued from the exercise of warrants (warrant shares)	538,150	538,150
Exercise price per warrant shares (in Dollars per share and Dollars per share) | (per share)	$ 1.077	$ 1.077
Expiry date	Apr. 05, 2028
November 23, 2024 [Member]
Schedule of Share Purchase Warrants were Outstanding [Line Items]
Number of warrants outstanding	75	75
Number of shares to be issued from the exercise of warrants (warrant shares)	75	75
Exercise price per warrant shares (in Dollars per share and Dollars per share) | (per share)	$ 1,293.48	$ 1,800
Expiry date	Nov. 23, 2024
September 17, 2028 [Member]
Schedule of Share Purchase Warrants were Outstanding [Line Items]
Number of warrants outstanding	2,352,504	2,352,504
Number of shares to be issued from the exercise of warrants (warrant shares)	677,683	677,683
Exercise price per warrant shares (in Dollars per share and Dollars per share) | (per share)	$ 1.077	$ 1.077
Expiry date	Sep. 17, 2028
January 15, 2029 [Member]
Schedule of Share Purchase Warrants were Outstanding [Line Items]
Number of warrants outstanding	1,331,480	1,331,480
Number of shares to be issued from the exercise of warrants (warrant shares)	1,331,480	1,331,480
Exercise price per warrant shares (in Dollars per share and Dollars per share) | (per share)	$ 1.6	$ 1.6
Expiry date	Jan. 15, 2029

Stock Options (Details)

Stock Options (Details)							12 Months Ended
	Nov. 14, 2023	Jul. 06, 2023 $ / shares	Jun. 26, 2023 $ / shares	Jun. 26, 2023 $ / shares	May 23, 2023 $ / shares	May 23, 2023 $ / shares	Oct. 31, 2024 USD ($)	Oct. 31, 2023 USD ($)
Stock Options [Line Items]
Percentage of issued and outstanding common shares	20%
Stock options award granted vest term	10 years
Common shares reserved for issuance period							12 months
Issued and outstanding common shares in total							15%
Stock options to consultant		50	223	223	61	61
Options exercisable per share | (per share)		$ 23.4	$ 363.35	$ 504	$ 227.09	$ 315
Options are exercisable			156	156
Expected volatility of share price							8 years 7 months 6 days
Share-based compensation expense (in Dollars)							$ 79,005	$ 221,625
Share Options [Member]
Stock Options [Line Items]
Options exercisable per share | (per share)			$ 519.07	$ 720
Options are exercisable			67	67
Related Party Consultant [Member]
Stock Options [Line Items]
Percentage of issued and outstanding common shares							5%
Investors [Member]
Stock Options [Line Items]
Percentage of issued and outstanding common shares							2%
Common shares reserved for issuance period							12 months

Stock Options - Schedule of Cha

Stock Options - Schedule of Changes in Stock Options (Details)	12 Months Ended
	Oct. 31, 2024 $ / shares	Oct. 31, 2024 $ / shares $ / shares	Oct. 31, 2023 $ / shares		Oct. 31, 2023 $ / shares		Oct. 31, 2024 $ / shares
Schedule of Changes in Stock Options [Abstract]
Number of options Outstanding, Beginning balance	5,588	5,588	5,254		5,254
Weighted average exercise price Outstanding, Beginning balance | (per share)	$ 434.82	$ 603.12	$ 450.64		$ 613.5
Number of options, Granted			334	[1],[2],[3]	334	[1],[2],[3]
Weighted average exercise price, Granted | (per share)			$ 318.81	[1],[2],[3]	$ 442.22	[1],[2],[3]
Number of options Outstanding, Ending balance	5,521	5,521	5,588		5,588
Weighted average exercise price Outstanding, Ending balance | (per share)	$ 432.38	$ 601.71	$ 434.82		$ 603.12
Number of options Outstanding, Exercisable	5,351	5,351					5,351
Weighted average exercise price Outstanding, Exercisable | (per share)	$ 433.67	$ 433.67					$ 603.5
Number of options, Expired	(67)	(67)
Weighted average exercise price, Expired | (per share)	$ 533.14	$ 720
[1] On July 6, 2023, the Company granted 50 stock options to a consultant of the Company. The options are exercisable at $23.40 per share. The options expire on July 6, 2033. On June 26, 2023, the Company granted 223 stock options to a consultant of the Company. The 156 options are exercisable at $363.35 (CAD$504.00) per share and the 67 options are exercisable at $519.07 (CAD$720.00) per share. The options expire on June 26, 2033. On May 23, 2023, the Company granted 61 stock options to a consultant of the Company. The options are exercisable at $227.09 (CAD$315.00) per share. The options expire on May 23, 2033.

Stock Options - Schedule of Add

Stock Options - Schedule of Additional Information Regarding Stock Options Outstanding (Details)	12 Months Ended
	Oct. 31, 2024 $ / shares	Oct. 31, 2024 $ / shares
Stock Outstanding [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	5,521	5,521
Weighted average remaining contractual life (years) Outstanding	4 years 7 months 24 days
Weighted average exercise price Outstanding | (per share)	$ 432.38	$ 601.71
Stock Outstanding [Member] | 533 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	533	533
Weighted average remaining contractual life (years) Outstanding	1 year 6 months 25 days
Weighted average exercise price Outstanding | (per share)	$ 119.65	$ 166.5
Stock Outstanding [Member] | 978 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	978	978
Weighted average remaining contractual life (years) Outstanding	7 years 3 months 3 days
Weighted average exercise price Outstanding | (per share)	$ 362.17	$ 504
Stock Outstanding [Member] | 1,166 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	1,166	1,166
Weighted average remaining contractual life (years) Outstanding	1 year 6 months 21 days
Weighted average exercise price Outstanding | (per share)	$ 485.05	$ 675
Stock Outstanding [Member] | 200 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	200	200
Weighted average remaining contractual life (years) Outstanding	4 years 5 months 26 days
Weighted average exercise price Outstanding | (per share)	$ 504.46	$ 702
Stock Outstanding [Member] | 133 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	133	133
Weighted average remaining contractual life (years) Outstanding	1 year 10 months 17 days
Weighted average exercise price Outstanding | (per share)	$ 536.79	$ 747
Stock Outstanding [Member] | 422 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	422	422
Weighted average remaining contractual life (years) Outstanding	7 years 1 month 9 days
Weighted average exercise price Outstanding | (per share)	$ 439.78	$ 612
Stock Outstanding [Member] | 1,044 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	1,044	1,044
Weighted average remaining contractual life (years) Outstanding	7 years 3 months 3 days
Weighted average exercise price Outstanding | (per share)	$ 517.39	$ 720
Stock Outstanding [Member] | 667 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	667	667
Weighted average remaining contractual life (years) Outstanding	1 year 8 months 1 day
Weighted average exercise price Outstanding | (per share)	$ 543.26	$ 756
Stock Outstanding [Member] | 111 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	111	111
Weighted average remaining contractual life (years) Outstanding	7 years 1 month 9 days
Weighted average exercise price Outstanding | (per share)	$ 646.74	$ 900
Stock Outstanding [Member] | 61 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	61	61
Weighted average remaining contractual life (years) Outstanding	8 years 6 months 21 days
Weighted average exercise price Outstanding | (per share)	$ 226.36	$ 315
Stock Outstanding [Member] | 156 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	156	156
Weighted average remaining contractual life (years) Outstanding	8 years 7 months 28 days
Weighted average exercise price Outstanding | (per share)	$ 362.17	$ 504
Stock Outstanding [Member] | 50 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	50	50
Weighted average remaining contractual life (years) Outstanding	8 years 8 months 4 days
Weighted average exercise price Outstanding | (per share)	$ 23.4	$ 32.56
Stock Exercisable [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	5,351	5,351
Weighted average exercise price, Exercisable | (per share)	$ 433.67	$ 603.5
Stock Exercisable [Member] | 533 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	533	533
Weighted average exercise price, Exercisable | (per share)	$ 119.65	$ 166.5
Stock Exercisable [Member] | 978 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	920	920
Weighted average exercise price, Exercisable | (per share)	$ 362.17	$ 504
Stock Exercisable [Member] | 1,166 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	1,166	1,166
Weighted average exercise price, Exercisable | (per share)	$ 485.05	$ 675
Stock Exercisable [Member] | 200 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	200	200
Weighted average exercise price, Exercisable | (per share)	$ 504.46	$ 702
Stock Exercisable [Member] | 133 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	133	133
Weighted average exercise price, Exercisable | (per share)	$ 536.79	$ 747
Stock Exercisable [Member] | 422 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	422	422
Weighted average exercise price, Exercisable | (per share)	$ 439.78	$ 612
Stock Exercisable [Member] | 1,044 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	957	957
Weighted average exercise price, Exercisable | (per share)	$ 517.39	$ 720
Stock Exercisable [Member] | 667 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	667	667
Weighted average exercise price, Exercisable | (per share)	$ 543.26	$ 756
Stock Exercisable [Member] | 111 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	111	111
Weighted average exercise price, Exercisable | (per share)	$ 646.74	$ 900
Stock Exercisable [Member] | 61 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	61	61
Weighted average exercise price, Exercisable | (per share)	$ 226.36	$ 315
Stock Exercisable [Member] | 156 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	156	156
Weighted average exercise price, Exercisable | (per share)	$ 362.17	$ 504
Stock Exercisable [Member] | 50 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	25	25
Weighted average exercise price, Exercisable | (per share)	$ 23.4	$ 32.56

Stock Options - Schedule of Fai

Stock Options - Schedule of Fair Value of Stock Options (Details) - Black-Scholes Option Pricing Model [Member]	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Schedule of Fair Value of Stock Options [Line Items]
Risk-free interest rate	4.22%	4.10%
Expected life (in years)	4.61	5.61
Bottom of Range [Member]
Schedule of Fair Value of Stock Options [Line Items]
Expected volatility	125.77%	140.41%
Top of Range [Member]
Schedule of Fair Value of Stock Options [Line Items]
Expected volatility	133.62%	160.81%

Restricted Share Units (Details

Restricted Share Units (Details) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 30, 2024	Oct. 31, 2022	Feb. 14, 2022
Restricted Share Units [Line Items]
Restricted shares units, issued (in Shares)			80,000		2,208
Fair value	$ 804,962	$ 91,589
Restricted Share Units [Member]
Restricted Share Units [Line Items]
Restricted shares units, issued (in Shares)	264,338	2,216		1,407
Consultants Directors And Officers [Member] | Restricted Share Units [Member]
Restricted Share Units [Line Items]
Restricted shares units, issued (in Shares)	591,460

Restricted Share Units - Schedu

Restricted Share Units - Schedule of Changes in RSUs (Details) - Restricted Share Units [Member]	12 Months Ended
	Oct. 31, 2024 $ / shares shares		Oct. 31, 2024 $ / shares shares		Oct. 31, 2023 $ / shares shares	Oct. 31, 2023 $ / shares shares
Restricted Share Units - Schedule of Changes in RSUs (Details) [Line Items]
Number of RSUs, Beginning balance	2,216		2,216		1,407	1,407
Weighted Average Issue Price, Beginning balance | (per share)	$ 96.06		$ 138.55		$ 273.42	$ 375.54
Number of RSUs, Granted	591,460	[1]	591,460	[1]	2,200	2,200
Weighted average issue price, Granted | (per share)	$ 1.36	[1]	$ 1.86	[1]	$ 41.63	$ 55.97
Number of RSUs, Exercised	(329,338)		(329,338)		(1,391)	(1,391)
Weighted Average Issue Price, Exercised | (per share)	$ 1.65		$ 2.22		$ 189.37	$ 246.64
Number of RSUs, Ending Balance	264,338		264,338		2,216	2,216
Weighted average issue price, Ending Balance | (per share)	$ 1.8		$ 2.55		$ 96.06	$ 138.55
[1] During the year ended October 31, 2024, the Company issued 591,460 RSU’s to consultants, directors and officers. The RSU’s vested with a fair value of $804,962 (2023-$91,589).

Financial Instruments and Ris_3

Financial Instruments and Risk Management (Details)	12 Months Ended
	Oct. 31, 2024
Financial Instruments and Risk Management [Line Items]
Foreign currency, percentage	10%
Foreign Exchange Rate Risk [Member]
Financial Instruments and Risk Management [Line Items]
Foreign currency, percentage	10%

Financial Instruments and Ris_4

Financial Instruments and Risk Management - Schedule of Assets and Liabilities Measured at Fair Value (Details) - USD ($)	Oct. 31, 2024	Oct. 31, 2023
Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Short-term investment- shares	$ 110,400	$ 86,112
Short-term investment- Polyrizon Warrants	178,988
Derivative warrant liabilities	3,519,702	4,310,379
Quoted prices in active markets for identical instruments (Level 1) [Member] | Recurring {Member}
Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Short-term investment- shares	110,400	86,112
Short-term investment- Polyrizon Warrants
Derivative warrant liabilities
Significant other observable inputs (Level 2) [Member] | Recurring {Member}
Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Short-term investment- shares
Short-term investment- Polyrizon Warrants
Derivative warrant liabilities
Significant unobservable inputs (Level 3) [Member] | Recurring {Member}
Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Short-term investment- shares
Short-term investment- Polyrizon Warrants	178,988
Derivative warrant liabilities	$ 3,519,702	$ 4,310,379

Financial Instruments and Ris_5

Financial Instruments and Risk Management - Schedule of Foreign Currency Exchange Risk on Net Working Capital (Details) - Foreign Exchange Rate Risk [Member]	12 Months Ended
	Oct. 31, 2024 USD ($)
Financial Instruments and Risk Management - Schedule of Foreign Currency Exchange Risk on Net Working Capital (Details) [Line Items]
Cash and cash equivalents	$ 137,666
Amounts receivable	49,038
Accounts payable and accrued liabilities	(192,971)
Due to related parties	(38,962)
Total foreign currency financial assets and liabilities	(45,229)
Impact of a 10% strengthening or weakening of foreign exchange rate	$ (4,523)

Financial Instruments and Ris_6

Financial Instruments and Risk Management - Schedule of Foreign Currency Exchange Risk on Net Working Capital (Parentheticals) (Details)	12 Months Ended
	Oct. 31, 2024
Foreign Exchange Rate Risk [Member]
Financial Instruments and Risk Management - Schedule of Foreign Currency Exchange Risk on Net Working Capital (Parentheticals) (Details) [Line Items]
Impact of a strengthening or weakening of foreign exchange rate	10%

Financial Instruments and Ris_7

Financial Instruments and Risk Management - Schedule of Contractual Maturities of Financial Liabilities (Details) - USD ($)	Oct. 31, 2024	Oct. 31, 2023
Schedule of Contractual Maturities of Financial Liabilities [Line Items]
Accounts payable and accrued liabilities	$ 526,056	$ 617,004
Due to related parties	48,962	42,433
Lease liability	53,142
Total	628,160	659,437
Within 1 year [Member]
Schedule of Contractual Maturities of Financial Liabilities [Line Items]
Accounts payable and accrued liabilities	526,056	617,004
Due to related parties	48,962	42,433
Lease liability	36,726
Total	611,744	659,437
Within 2-5 years [Member]
Schedule of Contractual Maturities of Financial Liabilities [Line Items]
Accounts payable and accrued liabilities
Due to related parties
Lease liability	16,416
Total	$ 16,416

Commitments (Details)

Commitments (Details) - USD ($)				12 Months Ended
	Mar. 31, 2024	Mar. 19, 2024	Jan. 15, 2024	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2022
Commitments [Line Items]
Percentage of royalities	3%	3%	1.50%
Annual maintenance fees				$ 1,998,625	$ 2,210,795	$ 1,093,871
Bottom of Range [Member]
Commitments [Line Items]
Annual maintenance fees	$ 25,000	$ 25,000
Top of Range [Member]
Commitments [Line Items]
Annual maintenance fees	$ 50,000	$ 50,000

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2022
Income Taxes [Line Items]
Provincial statutory income tax rate	27%	27%	27%
Statutory corporate tax rate	23%	23%	23%
Canada [Member]
Income Taxes [Line Items]
Non-capital losses carried forward (in Dollars)	$ 20,281,000

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2022
Schedule of Deferred Income Tax Assets and Liabilities [Abstract]
Canadian statutory income tax rate	27%	27%	27%
Income tax recovery at statutory rate	$ (1,316,712)	$ (2,322,936)	$ (1,861,476)
Tax effect of:
Items not deductible for tax purposes	(20,556)	223,809	335,494
Over provided in prior years	(384,109)	(19,674)
Tax rate difference for foreign jurisdiction	(5,365)	10,715	56,175
Change in unrecognized deferred income tax assets	2,104,708	2,125,459	1,499,666
Income tax provision	$ 377,966	$ 17,372	$ 29,859

Income Taxes - Schedule of Cana

Income Taxes - Schedule of Canadian Non-Capital Losses Carried Forward (Details)	Oct. 31, 2024 USD ($)
Schedule of Canadian Non-Capital Losses Carried Forward [Line Items]
Total non-capital losses carried forward	$ 20,281,000
2037 [Member]
Schedule of Canadian Non-Capital Losses Carried Forward [Line Items]
Total non-capital losses carried forward	5,000
2038 [Member]
Schedule of Canadian Non-Capital Losses Carried Forward [Line Items]
Total non-capital losses carried forward	73,000
2039 [Member]
Schedule of Canadian Non-Capital Losses Carried Forward [Line Items]
Total non-capital losses carried forward	71,000
2040 [Member]
Schedule of Canadian Non-Capital Losses Carried Forward [Line Items]
Total non-capital losses carried forward	169,000
2041 [Member]
Schedule of Canadian Non-Capital Losses Carried Forward [Line Items]
Total non-capital losses carried forward	1,142,000
2042 [Member]
Schedule of Canadian Non-Capital Losses Carried Forward [Line Items]
Total non-capital losses carried forward	4,716,000
2043 [Member]
Schedule of Canadian Non-Capital Losses Carried Forward [Line Items]
Total non-capital losses carried forward	8,678,000
2044 [Member]
Schedule of Canadian Non-Capital Losses Carried Forward [Line Items]
Total non-capital losses carried forward	$ 5,427,000

General and Administrative Ex_3

General and Administrative Expenses - Schedule of General and Administrative Expenses (Details) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2022
Schedule of General and Administrative Expenses [Abstract]
Professional fees	$ 1,998,625	$ 2,210,795	$ 1,093,871
Investor relations	440,041	1,565,970	473,106
Share-based compensation	1,119,041	243,717	946,324
Consulting fees	131,769	96,421	192,448
Insurance	329,278	364,059	149,537
Transfer agent and regulatory fees	190,397	171,439	86,605
Depreciation of ROU asset	39,023	35,381	60,665
Salaries and benefits	57,340	37,838	92,296
Office and miscellaneous	55,538	31,670	68,016
Depreciation of property and equipment	1,065	1,915	7,572
Total general and administrative	$ 4,362,117	$ 4,759,205	$ 3,170,440

Research and Development, Net -

Research and Development, Net - Schedule of Research and Development, Net (Details) - USD ($)	12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2022
Schedule of Research and Development, Net [Abstract]
Research and preclinical studies	$ 747,026	$ 1,159,147	$ 2,380,942
Salaries, regulatory, professional and other expenses	542,615	469,667	666,125
Share-based compensation (Notes 6, 10 and 11)	132,502	45,870	213,299
Reimbursements (Note 6)	(50,319)	(141,409)	(194,205)
Amortization of intangible assets	10,984	10,954	14,830
Total research and development, net	$ 1,382,808	$ 1,544,229	$ 3,080,991

Subsequent Events (Details)

Subsequent Events (Details) - Non-Adjusting Events After Reporting Period [Member] - USD ($)	Dec. 26, 2024	Nov. 30, 2024
Subsequent Events [Line Items]
Total proceeds		$ 82,961
Warrant exercised of common share (in Shares)	310,388
Warrants exercised for gross proceeds	$ 441,577